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ABSTRACT 
Poly (adenine diphosphate-ribosyl)ation of a variety of nuclear proteins is the 
immediate response in most eukaryotic cells to DNA strand breaks. This modification 
is catalysed' by the chromatin bound enzyme Poly (ADP-ribose) polymerase 
(PADPRP). The enzyme is thought to be intimately involved in several cellular 
processes including cell differentiation, gene expression, transformation of oncogenes 
and repair of DNA damage. As a consequence, inhibitors of PADPRP are able to 
potentiate the cytotoxicity of many anti-tumour agents whose actions include DNA 
damage, and as such these inhibitors are potential resistance-modifying agents for use 
in cancer therapy. 
In order to probe the active site of the enzyme a series of potential mimics (i) of NAD' 
were synthesised from readily available 3-hydroxybenzamide. 
i ii iii 
The conformation of the amide bond is considered to be important and for increased 
potency the amide carbonyl should be anti with respect to the nicotinamide C2-C3 
bond. Based on this reported observation a series of novel inhibitors were synthesised, 
which include a series of benzoxazole-4-carboxamide analogues (ii) and 8-hydroxy-2- 
(substituted)quinazolin-4-one analogues (iii). The structure of the benzoxazole 
analogues are such that the amide is anchored into the required conformation by an 
X 
intramolecular hydrogen bond between the carboxamide N-H and the benzoxazole 
nitrogen. 
The benzyloxybenzamide analogues had comparable potency to 3-hydroxybenzamide 
against PADPRP. However, both the benzoxazole-4-carboxamide and 8-hydroxy 
quinazolin-4-one series of analogues exhibited outstanding inhibitory activity against 
PADPRP. The most potent of the benzoxazole-4-carboxamide analogues (ii, R= 
phenyl) had an IC50 value of 2.1 p. M. Exceptional PADPRP inhibitory activity was 
observed in the 8-hydroxyquinazolin-4-one (iii) series, where R= CH3 (IC50 = 0.4 µ 
M) and R= 4-nitrophenyl (IC50 = 0.2 µM). Further in vitro evaluation has shown that 
8-hydroxy-2-methylquinazolin-4[3H]-one potentiates cytotoxicity in temozolomide 
treated cells. 
I 
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CHAPTER ONE 
1.0 INTRODUCTION 
Cancer is the second most common cause of death after cardiovascular disease in 
developed countries, accounting for nearly 1 in 5 deaths. 1 The reported incidence 
of cancer has increased dramatically as other once fatal diseases, such as smallpox, 
have been virtually eradicated. As life expectancy increases so do the number of 
deaths linked to cancer. 
Presently there are three major weapons against cancer: surgery, radiotherapy and 
chemotherapy, which can either be used alone or in combination. Surgery and 
radiotherapy are normally used to treat primary tumours. Chemotherapy is used to 
treat both primary and secondary metastatic cancers. Unfortunately, chemotherapy 
frequently fails because the tumour becomes resistant to the administered drug. 
1.1. Resistance in Cancer Chemotherapy 
Resistance may be either intrinsic or acquired. 2-7 
Intrinsic or primary resistance is when cells in the tumour do not respond to initial 
chemotherapy. 
Acquired or secondary resistance arises when tumour cells respond initially to 
therapy but eventually tumour growth resumes. This type of resistance may be due 
to either a genetic or epigenetic change in these tumour cells. 
1 
Mechanisms of Resistance 
Primary resistance is not completely understood as it is difficult to replicate under 
laboratory conditions. Therefore, it is assumed that the mechanisms of intrinsic 
resistance are similar to those of acquired resistance. Acquired resistance has been 
widely studied and there are many proposed mechanisms of acquired drug 
resistance which include: 
Altered membrane transport: Many drugs are dependent on a cellular transport 
system for cell entry. Therefore, loss or inactivation of this system may lead to 
resistance. Also in the cell membrane there are a variety of plasma membrane 
proteins (P-glycoproteins) which are responsible for the export of lipophilic drugs 
from the cell. Overexpression of P-glycoproteins, particularly P-170, causes the 
efflux of large hydrophobic drugs, which results in non-specific multidrug 
resistance. 
Altered drug activation: Many drugs are introduced into the body as prodrugs, that 
is, they require metabolic activation before their cytotoxic potential can be realised. 
For many prodrugs the activator is an enzyme. Thus, a decrease in the activating 
enzyme means that the drug will remain in the inactive prodrug form. 
Altered drug-target complex: This encompasses a wide range of resistance 
mechanisms, which include: 
a. A specific mutation in the target enzyme causing decreased affinity of the 
enzyme for the drug. 
b. Overexpression of the target enzyme which will swamp the drug, making it 
difficult to achieve complete inhibition. 
c. An increase in the normal substrate which will decrease the likelihood of the 
drug binding to the target enzyme. 
2 
Increased tolerance to the drug: Any route which allows the cell to circumvent 
the effect caused by the drug falls in this category. An example of this is the role of 
nucleoside transport in antimetabolite chemotherapy. Nucleoside uptake allows the 
cell to bypass blocks in the de novo purine and pyrimidine synthesis and evade the 
DNA synthesis block. 
Enhanced DNA repair: Many antitumour drugs eventually kill the cell by DNA 
damage. The cell may counteract this increased DNA damage by increasing the 
amount of DNA repair enzymes present, thus, reducing the amount of damage done 
by the carcinostatic drug. There are multiple mechanisms for DNA repair, and 
several hundred genes are involved in this process. 
As there are a number of anticancer drugs which interact with DNA, such as by 
intercalation and alkylation, it is likely that DNA repair is of significant value in the 
development of resistance. 
Figure: 1.1.1. Cartoon shoving simplified mechanisms of biochemical drug resistance 
drug 
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1.2. DNA Repair 
Carcinogenic agents are involved in the disruption or mutation of DNA. After 
DNA damage the cell has three options: the damaged region may be repaired, 
deleted or retained. If the lesion is retained then the cell may die, or possibly 
become neoplastic. Generally, the cell will implement the appropriate repair 
mechanism and repair the damage. 2 
Mechanisms of Repair 
DNA repair mechanisms fall into two broad categories: reversal of damage and 
excision repair. 
Reversal of Damage: 
O6 Methylguanine DNA methyl transferase (MGMT) reverses DNA damage by 
removing covalent alkyl groups from the 06 position of guanine, transferring the 
alkyl moiety to a cysteine residue in the active site, and hence repairing DNA. 
DNA ligase seals single DNA strand breaks which have no missing nucleotides and 
juxtaposed 3'-hydroxy and 5'-phosphate termini. Ligation has also been indicated as 
the final step in excision repair mechanisms. 
Excision of Damage 
Base excision repair and nucleotide excision repair mechanisms cover a host of 
different glycosylases, endonucleases and exonucleases, all of which are involved in 
the incision or excision of damaged DNA. In some cases, when only the base has 
been damaged, such as by alkylation of purines, then glycosylases excise the base by 
hydrolysis of the N-glycosidic bond. However, if the DNA has been altered by a 
change in conformation, such as occurs in the formation of pyrimidine dimers, then 
the damaged section will be removed as part of a small oligonucleotide. 
4 
Regardless of the method of excision the damage has not been repaired until the 
missing nucleotides are replaced. DNA polymerases replace the missing segment of 
DNA and the strand is re-annealed via the action of DNA ligases. 
i Figure: 1.2.1 Simplified mechanisms for DNA repair 
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There are many enzymes and proteins which have been indicated in post-incision 
events during excision repair. Although the principal proteins have been mentioned, 
there are other enzymes which may be intimately involved in repair of DNA in vivo. 
One of these is Poly (adenine diphosphate ribose)polymerase (PADPRP). Whilst 
PADPRP is apparently neither required for incision nor is involved in repair 
synthesis, inhibition of this enzyme nevertheless produces a synergistic increase in 
cell kill after treatment of cells with radiation or monofunctional alkylating 
agents. 8,9 
1.3. Resistance Modification 
Resistance to chemotherapy is probably one of the most important therapeutic 
problems in medical oncology. Whilst there are many mechanisms of resistance and 
thus, many ways of overcoming resistance, exploitation of the increased DNA 
repair mechanisms in the cell may be one method of resistance modification. 
Research is currently underway into inhibition of the most studied of the repair 
proteins, MGMT. Treatment with an alkylating agent, whilst inhibiting MGMT, 
would render the cell incapable of repair, thus causing cell death. This strategy may 
be applied to, and indeed, has been applied to other DNA repair proteins. In 
ovarian cancer the drug aphidicolin, a potent inhibitor of both a and ß DNA 
polymerases, can restore tumour sensitivity to L-phenylanine mustard and cisplatin 
in otherwise drug-resistant tumours. ` 
Similarly, suppression of PADPRP may have beneficial effects, since PADPRP is 
activated by DNA damage, particularly single strand breaks rather than DNA 
mutations. It is an ideal target for overcoming resistance in otherwise unresponsive 
tumours, by potentiating DNA damaging agents. 
6 
1.4. Poly (Adenine Diphosphate Ribose) Polymerase (PADPRP) 
Poly (adenine diphosphate ribosyl)ation is a significant post translational 
modification involving the covalent attachment of long negatively charged 
homopolymers to a variety of nuclear proteins, particularly histones. This 
dramatically alters the chromatin structure, thus affecting functions such as gene 
expression, 10-12 DNA replication, 13 DNA repair, 14-16 differentiationl0,11,14 and 
apoptosis. 17,18 
Historical Background 
The enzyme poly (ADP-ribose) polymerase [EC 2.4.2.30] was discovered in the 
early 1960's by Mandel et al, 19 who observed that [14C Adenine] ATP was 
incorporated into an acid soluble fraction of hen liver nuclei, and that this 
phenomenon could be stimulated by addition of nicotinamide mononucleotide. It 
was later confirmed by the same group, that the isolated product was a 
homopolymer of repeating (ADP) ribose units. 20 Since this discovery there has 
been much interest in PADPRP as to its function in the eukaryotic cell and its 
effects on DNA and gene expression. 9-11,18,21,22 
Enzyme Structure 
PADPRP is a highly conserved nuclear enzyme of 116 Kda (1014 amino acids) and 
is present in most eukaryotic cells, including insects and lower order eukaryotes. 
By limited proteolysis the enzyme was found to contain three major domains. 23 
The 46Kda amino terminal domain is highly charged and contains two homologous 
sequences (2-97 and 106-207) which form two zinc fingers. It is these zinc fingers 
which are responsible for binding the enzyme to DNA strand breaks. 24,25 
7 
The 22Kda central domain contains the automodification sequence and is rich in 
lysine and glutamic acid. Glutamic acid residues have been shown to be the primary 
automodification sites, hence there is a perfect coincidence between the number of 
glutamic acid residues in this domain and the number of automodification sites 
identified. 
The 54Kda carboxyl terminal domain is the most highly conserved domain 
containing the carboxyl terminal region of PADPRP. The NAD+ binding site is 
situated within a strictly conserved region in this domain This region has 99 % 
conservation between vertebrates and 92 % conservation between all species, and is 
known as the 'PADPRP signature'. 26 
1.5. Biosynthesis of the Polymer 
PADPRP catalyses the transfer of ADP ribose from NAD+ (Figure: 1.5.1. ) to a 
nuclear protein acceptor, generating mono, oligo and poly (ADP)ribose tails 
(Figure: 1.5.2). 
Figure. 1.5.1. Nicotinamide adenine dinucleotide 
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Figure 1.5.2. Metabolism of (ADP) ribose polymers 
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Mechanism of Action 
Cleavage of the nicotinamide-ribose bond may be facilitated by donation of the 
adjacent ribose oxygen electron lone pair. This type of assistance has been well 
documented for the lysozyme mediated hydrolysis of bacterial cell walls. 
Lysozymes, are widespread in biological tissues and secretions. Their exact 
function is still not clear, but their mechanism of action has been extensively 
studied. 27 Phillips proposed a mechanism based on structural studies of lysozyme 
and a knowledge of acetal hydrolysis. 28 
After the lysozyme has bound to the bacterial cell wall, the glycoside involved in the 
hydrolysis reaction is distorted into a sofa conformation, and Glu-35 donates a 
proton to the exocyclic oxygen. Cleavage of the C-O-RI moiety is assisted by 
donation from the neighbouring oxygen forming a resonance stabilised oxonium 
species. During hydrolysis the negatively charged Asp-52 acts to stabilise the 
oxonium species through a charge-charge interaction. Finally, water is added and 
Glu-35 becomes reprotonated, with subsequent release of the hemiacetal from the 
enzyme active site completing the process (Figure: 1.5.3. ). 
This reaction mechanism can be considered because PADPRP hydrolyses the 
nicotinamide-ribose bond in a manner comparable to that of lysozyme hydrolysis. 
Slama and Simmons proposed that cleavage of the pyridinium ribose bond is 
facilitated by an analogous assistance from the ribose oxygen. 29.30 Such assistance 
may be achieved by the ribose adopting an envelope conformation, thus maximising 
orbital overlap from a lone pair of electrons in the pseudoaxial position on oxygen 
with the ß* orbital on carbon to form an sp2 hybridised oxonium species. This 
would facilitate C-N bond cleavage with loss of nicotinamide (Figure: 1.5.4. ). 
10 
Figure: 1.5.3. Proposed mechanism of lysozyme hydrolysis 
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Figure 1.5.4. Proposed SN 1 mechanism of PADPRP-catalysed NAD+ cleavage 
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Schuber et al have been exploring the mechanism of NAD+ glycohydrolases, and 
have chemical evidence in favour of a stabilised oxonium intermediate in the NAD+ 
glycohydrolase catalysed reactions. 31 The authors compared the effects of solvent 
on the rate of spontaneous solvolysis of NAD+ with that of enzyme catalysed 
solvolysis, in order to determine whether NAD+ glycohydrolase stabilises the ADP- 
12 
ribosyl species. Their findings confirm the work of Jencks and Young 31 in that the 
oxonium ion would be too unstable to exist as a free solvent-equilibrated 
intermediate, and that in the example of non-catalysed solvolysis there may be an 
enforced preassociated mechanism where the oxonium species is stabilised by the 
leaving nicotinamide and the attacking solvent molecules in an SN2 type reaction. 
Conversely, the enzyme catalysed solvolysis studies indicate that the mechanism of 
oxonium ion formation is by an SN1 style mechanism in which the oxonium ion is 
stabilised by the glycohydrolase. The stabilisation effects are considerable because 
the lifetime of the oxonium-enzyme species is long enough to allow the diffusion of 
nicotinamide out of the active site before nucleophilic attack at the carbon centre, 
because the stereochemistry of solvolysis is with retention of configuration. 31 
Catabolism of the Polymer 
There are two main enzymes involved in the breakdown of (ADP) ribose polymers. 
PADPRP glycohydrolase degrades the ribose-ribose bond in both linear and 
branched chains from the 2' position, 32-32 and a eukaryotic phosphodiesterase 
attacks the pyrophosphate bond in the polymers. 35,36 Once the long (ADP-ribose) 
polymers have been degraded, (ADP)ribose protein lyase is responsible for removal 
of the final (ADP)ribose moiety from an automodified polymerase, thus releasing 
the enzyme and allowing it to reassociate with other DNA strand breaks. 37 
1.6. Mechanisms of Polymer Growth 
There are two possible mechanisms for the progressive addition of the polymer tail, 
either distal or proximal depending upon the acceptor protein. If the acceptor is 
any other protein but PADPRP itself then distal addition may occur. However, if 
PADPRP is the acceptor, and as such is being automodified, then the proximal 
model may possibly take precedence. 
13 
Distal Addition 
Polymerisation of a single ADP ribose residue added to the free 2' OH will build up 
the polymer. This kind of polymer addition occurs for (ADP ribosyl)ation of most 
nuclear protein acceptors. 9 
Figure: 1.6.1 Distal addition 
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If PADPRP underwent automodification via a distal type mechanism, then a second 
PADPRP and glycohydrolase may compete for the same 2'-OH site. The proximal 
model shows polymer growth via the addition of the ADP-ribose unit initially 
binding from the 1'-OH position of NAD+ to the NAD+ binding site in PADPRP. 
Subsequent transfer of the existing polymer to the monomer's 2'-OH position builds 
up the homo polymer tail, thus forming a shuttle type mechanism between two 
different sites on one polymerase. 3 8,39 
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Figure: 1.6.2. Proximal addition 
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As yet the exact mechanism is not known and these postulated mechanisms are still 
under considerable debate. Alvarez-Mendoza et al. have postulated that two 
PADPRP monomers are required for the progression of automodification, which 
infers that it is an intermolecular process rather than an intramolecular process. 40 
15 
(ADP"ribose) polymer 
1.7. Activation and Binding of PADPRP 
PADPRP has been shown to bind specifically to DNA strand breaks, but with no 
apparent sequence specificity. 41,42 Menissier de Murcia et al found, via an elegant 
series of experiments, that the two zinc fingers located in the amino terminal domain 
are responsible for the polymerase binding to DNA. Specific site mutagenesis in the 
gene which codes for PADPRP, to remove one of the zinc fingers, results in 
association with DNA double strand breaks only. Loss of both zinc fingers 
completely, prevents DNA binding and blocks activation of the enzyme by DNA 
strand breaks. 42 
Although PADPRP binds to DNA strand breaks in a zinc dependent manner, 41 the 
actual mechanism of binding and ribosylation is still unclear. Recently, de Murcia 
and Menissier de Murcia highlighted the binding specificity of PADPRP during 
automodification. 26 
Automodification of PADPRP 
When single strand breaks occur in the DNA duplex a certain amount of flexibility 
is introduced, and the structure adopts a 'V' conformation (Figure: 1.7.1). 
PADPRP binds specifically to the centre of the V, as observed by electron 
microscopy, 43 in a manner reminiscent of specific PADPRP binding to DNA 
cruciforms44 and crossovers45 (Figure: 1.7.2). The authors propose that the 
specific angle formed by the V may assist PADPRP binding. Also, the nick-induced 
flexibility may enable two PADPRP monomers to associate, one either side of the V 
shaped DNA strand break, thus initiating automodification. The possible role of 
automodified PADPRP in the cell nucleus has been investigated recently. 
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Figure: 1.7.1. V conformation adopted by DNA with a single strand break 
DNA damaging 
agent 
. r" 
lop' 
DNA duplex single strand break V conformation 
1.8. Biological Function of Poly (ADP ribosyl)ation 
Automodification and heteromodification of nuclear proteins, such as histones, 
generally inhibits their function. As PADPRP is intimately associated with 
chromatin the effects of such inhibition have been indicated in DNA replication, 13 
DNA repair, 14-16 cell survival, 17,18 gene expression and transformation. 10,11 
Before the DNA can be accessed by the many proteins and enzymes, the chromatin 
needs to be unravelled. A cell nucleus 8µm in diameter contains on average 5 
billion base pairs which total approximately 1.8 m in length; hence the DNA must 
be organised into several tiers. Initially the DNA is organised into nucleosomes 
which condense to form chromatin. 
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Figure: 1.7.2. Binding of two PADPRP monomers to a DNA strand break26 
DNA damaging 
agent 
DNA strand break 
PARP binding to the break 
Automodification of PARP 
also heteromodification of histones 
Eventual disassociation of 
PARP from DNA 
Facilitated access for 
repair enzymes? 
18 
catabolism metabolism 
Nucleosomes consist of nine nuclear proteins known as histones. Histones are basic 
proteins and can be classified according to amino acid content, marginally lysine 
rich (H2A and H2B), marginally arginine rich (H3 and H4) or exceptionally lysine 
rich (H1). All the histones appear to be significantly conserved between eukaryotic 
species, which implies that they have a specific role. Histones H2A and H2B form 
dimers whilst 2x (H3 and H4) form tetramers. These building blocks form the core 
of the nucleosome, with the DNA being wrapped around the surface of the 
octamer. 
The histone H1 seals the nucleosome where the DNA enters and leaves, thus 
protecting 166 base pairs of DNA. The nucleosomes are further condensed to form 
chromatin. Chromatin is held together by the interaction of histone H1 with the 
core histones of neighbouring nucleosomes. 
Figure: 1.8.1. Representation of chromatin 
nmA 
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The structure and modification of chromatin largely determines replication, repair, 
gene expression and other genomic processes. Histones, the nuclear matrix and 
indeed PADPRP itself are all acceptors for the (ADP) ribose polymer, but the 
combined effects of (ADPribosyl)ation on these proteins have yet to be elucidated. 
(ADP ribosyl)ation of histone H1 is particularly important since this protein not 
only closes its own nucleosome, but is responsible for the condensed state of the 
chromatin. Poirer et al observed that poly (ADP ribosyl)ation of histone H1 did 
relax chromatin, and this was confirmed by the inability of chromatin to condense to 
higher order structures in vitro, after poly (ADP ribosyl)ation. 46,4 
Automodification of PADPRP to form long homopolymeric chains may cause the 
histones to be pulled off the DNA and to associate with the polymer-polymerase- 
DNA complex, especially as histones H3 and H4, have an equal or higher affinity 
for (ADP) ribose branched polymers than for DNA alone. 26 Once the polymers 
reach a critical size the automodified PADPRP dissociates from the DNA strand 
break and the polymer is degraded. The histones, having lost the electrostatic 
attraction become reassociated with the DNA. This is known as histone shuttling. 
Heteromodification of histones adds a large negative charge which causes them to 
be repelled from DNA. Eventually PADPRP glycohydrolase degrades the (ADP) 
ribose polymers on the histones, thus reducing the negative charge. Consequently 
the histones become reassociated with DNA to reform the original structure of the 
nucleosome. This loosening of the chromatin structure may allow access of repair 
enzymes by either heteromodification 
automodification. 48 50 
or histone shuttling and 
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Figure: 1.8.2a. Possible involvement of automodified PADPRP in histone shuttling49 
Nuclear matrix proteins 
Automodified PARP 
H1 
I 
Nucleosome 
Figure: 1.8.2b. Automodified PADPRP releasing histones from the nucleosome 
Automodified PARP 
H1 
Free DNA 
Nucleosome 
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Nuclear matrix proteins 
Poly (ADP ribosyl)ation of other nuclear enzymes may assist this DNA repair. 
Topoisomerases and high mobility group proteins (HMG) are associated with 
regulating transcriptionally active chromatin, and ribosylation of these proteins 
renders them inactive thus causing cessation of transcription, recombination, 
replication etc. 51,52 PADPRP is activated by DNA strand breaks, therefore, for 
ribosylation to occur there must be local DNA damage. By inactivating the 
enzymes involved in DNA replication the cell has time to repair the damage. 
1.9. Inhibition of PADPRP 
Most research into PADPRP inhibitors have centred on the nicotinamide unit of 
NAD+, with benzamide being a classical NAD+ mimetic. Inhibitors of PADPRP 
were initially used to elucidate the function and physiological effects of the enzyme. 
These inhibitors included nicotinamide, 5-methylnicotinamide, 53 thymidine, 54 
theophylline and caffeine. 55 Unfortunately these inhibitors also cause other cellular 
dysfunctions. For example, nicotinamide affects NAD+ biosynthesis and depletes 
cellular phosphoribosyl diphosphate pools, leading to decreased nucleotide 
synthesis. 56 Thymidine is thought to inhibit DNA synthesis57 and xanthines are 
known to inhibit many enzymes, including the enzyme cyclic phosphodiesterase, and 
other cell functions. 58-60 Thus, if these inhibitors are utilised to elucidate 
PADPRP's biological function, any significant effects that result cannot be directly 
attributed to inhibition of this enzyme alone. 
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Figure: 1.9.1. Classical PADPRP inhibitors 
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H3 
/ NH2 
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Thymidine 
Theophylline Caffeine 
Benzamide has been shown to exhibit good inhibitory activity against PADPRP. 61 
The increased inhibitory activity, when compared to nicotinamide, can be attributed 
to the lack of a ring nitrogen, which confers stability to NAD+ metabolising 
enzymes. 
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02 
Benzamide 
Benzamide, however, has low aqueous solubility due to its hydrophobic nature, and 
this has caused problems in physiological buffer solutions. 
Purnell and Whish introduced substituted benzamides as potential PADPRP 
inhibitors. 56 They screened a series of benzamide analogues for inhibitory activity, 
and these included compounds substituted at the 3-position with amino, methoxy, 
bromo, hydroxy and nitro groups (Figure: 1.9.2. ). 
Figure: 1.9.2.3-Substituted benzamides as PADPRP inhibitors 
R=NH2 
R=OCHS 
R=Br 
R=OH 
R=N02 
R= NHCOCH3 
With the exception of 3-nitrobenzamide, the observed inhibitory activity was very 
high and all, including 3-nitrobenzamide, were considerably more potent than 
nicotinamide. Acylation of 3-aminobenzamide to form 3-acetamidobenzamide 
afforded one of the better PADPRP inhibitors. 
Sims et al screened a selection of nicotinamides, benzamides, pyrazinamides and 
purine analogues for their PADPRP inhibitory activity. Of the nicotinamides 
screened nicotinamide and picolinamide were the most potent. 62 Structural 
modifications to the parent compound resulted in either decreased or complete loss 
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of activity. Notably, modification of the amide had the most dramatic effect. The 
inhibitory activity decreased dramatically on mono- or di-substitution of the amide. 
Conversion to nicotinic acid also resulted in total loss of activity. Inactivity was 
similarly observed in an analogue which had a piperazine rather than an aromatic 
ring (Figure: 1.9.3. ). 
Figure: 1.9.3. Structural alteration of known PADPRP inhibitors 
LNHCH3 
I N(CH2CH3)2 
NN 
N-Methylnicotinamide N, N-Diethylnicotinamide 
00 
OH NHZ 
NN 
H 
Nicotinic acid Piperazine-3-carboxamide 
Classical bioisosteres of benzamide evaluated include those bearing other 
heteroatoms, for example sulfur. Cantoni et al examined three sulfur-containing 
analogues in order to elucidate PADPRP's dependency on dipole moments, 
hydrogen bond strength and steric hindrance of the amide. 63 Benzenesulfonamide 
and thiobenzamide were chosen for their obvious structural similarity to benzamide, 
and thiophene-3-carboxamide as a direct isostere of benzamide, with the divalent 
sulfur replacing the vinylic CH=CH. 
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Figure: 1.9.4. Sulfur containing PADPRP inhibitors 
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In vitro evaluation showed that benzenesulfonamide and thiobenzamide had no 
inhibitory activity, but thiophene carboxamide exhibited weak inhibitory activity 
against PADPRP. 
In an attempt to find more specific PADPRP inhibitors Banasik et al screened over 
two hundred compounds to determine inhibitory effects on PADPRP and mono 
(ADP)ribose polymerase. 64 All of the potent inhibitors, with the exception of the 
benzamides were polyaromatic. 4-Amino-1,8-naphthalimide was the most active 
against PADPRP with phenanthridinone having the same order of potency. The 
distinguishing feature of these inhibitors is that the carbonyl is restricted as part of a 
ring system conjugated to an aromatic ring. This reinforces the idea that a potent 
PADPRP inhibitor requires a carbonyl group pointing in the correct direction for 
binding to the enzyme. It was noted, however, that alkylation of the imide nitrogen 
in (N-2-chloroethyl)-4-amino-1,8-naphthalimide resulted in complete loss of 
activity. In view of previous literature reports, this was not surprising since it is 
believed that at least one amide proton is required to bind to the enzyme active site, 
thus conferring inhibitory activity (Table: 1.9. A. ). 62,65 
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Table: 1.9. A. Illustrative examples of known inhibitors 
structure compound IC50 µM 
200 µM NAD+ 
H 
ONO 
4-amino-1,8- 0.18 
naphthalimide 
NH2 
C 
NH N 
6[5H]-phenanthridinone 0.3 
- , 
0 
NOz 
2-nitro-6[5H]- 
phenanthridinone 0.35 
NH 
CHZCHZCI 
I 
N O 
(N-2-chloroethyl) 
4-amino-1,8- 1800 
naphthalimide 
NH2 
0 
NHZ 
YH 
3-hydroxybenzamide 1.9 
NH2 3-methylbenzamide 19 
O 
NHz 2-methylbenzamide 1500 
CHz 
NH2 
H3C 
4-methylbenzamide 1800 
27 
Among the benzamide analogues the authors found 3-hydroxybenzamide to be quite 
potent against PADPRP, whilst movement of the methyl substituent around the ring 
caused a severe loss of activity. 
After examining the proposed mechanism of NAD' cleavage by ADP-ribosyl 
transferases, Slama and Simmonds synthesised a carbanicotinamide analogue of the 
co-enzyme NAD+. Since enzymatic cleavage is thought to be assisted by electron 
donation (see p 11), replacement of the ribose oxygen by the isosteric CH2 affords a 
compound which should bind in a similar manner to NAD+, but whose nicotinamide 
bond will be significantly more stable to cleavage. 29 
The carbanicotinamide analogue initially evaluated for inhibitory activity was a 
mixture of diastereoisomers. Later studies, however, showed that the unnatural 
diastereoisomer (w carba NAD) was responsible for the observed inhibition and the 
natural isomer (carba NAD) had no effect on PADPRP. 30 Although there are no 
clear reasons for this selectivity, the authors propose that the presence of the 
isosteric CH2 in the dihydroxypentane ring in w carba NAD distorts the nucleotide 
into a conformation preferred for binding, whereas for the natural isomer the 
distortion is unfavourable for binding. Oppenheimer subsequently supported this 
theory by NMR studies (Figure: 1.9.5. ). 66 
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Figure: 1.9.5. Structural isomers of NAD+ 
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Further research into the preparation of the carba NAD includes the synthesis of a 
radiolabelled NAD, which may prove useful in determining NAD binding. 67 
1.10. Clinical use of PADPRP Inhibitors 
As PADPRP is involved in DNA repair, its inhibition can interfere with the repair of 
DNA lesions. Research has shown that inhibitors of PADPRP may enhance the 
cytotoxicity of DNA damaging agents. 8 9,18 Enhancement in the destruction of 
cells, by the administration of a PADPRP inhibitor with a DNA damaging agent, has 
tremendous implications for the treatment of cancer, particularly for tumours which 
have become resistant to standard chemotherapy. Concomitant dosing of a 
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PADPRP inhibitor with a DNA damaging agent may circumvent the mechanism of 
resistance, thus causing cytotoxicity in a tumour, resistant by virtue of enhanced 
PADPRP associated DNA repair. 
One of the earliest reports regarding the use of PADPRP inhibitors as resistance 
modifying agents in cancer chemotherapy was performed by Smulson et a1.68 Mice 
were injected with L1210 murine leukaemia cells intraperitoneally, and after 2 days 
were administered with either N-methyl-N-nitrosourea (MNU) alone or co- 
administered with nicotinamide. Those animals treated with MNU alone had an 
increased survival time in comparison to controls, but co-administration with 
nicotinamide increased the survival time over mice treated with MNU alone. 68 
Subsequent studies investigated the effects of PADPRP inhibitors on whole cell 
systems in vitro. Inhibitors of PADPRP have potentiated the cytotoxic effects of 
many DNA damaging agents (Table: 1.10. A. ). 
Table: 1.10. A. 
DNA damaging cell line inhibitor and modifying author 
agent concentration effect 
X-rays Chinese hamster 3-AB + BenHur 69 
ovary 20 mM 
y-rays mouse embryo benzamide + Kasid 
SALB 3T3 1-5 mM et aP0 
Dimethyl human 3-AB ++ James and 
sulphate fibroblast 5 mM Lehmann7l 
Methylnitroso- mouse nicotinamide 
urea lymphoma 2 mM +++ Nduka12 
(L1210) 
N-methyl-N'- mouse 3-MB Jacobson 
nitro-N- C3H/IOTI/2 1 mm ++ et aP2 
nitroso anidine 
3-AB, 3- Aminobenzamide; 3-MB, 3-Methoxybenzamide. 
+, small effect; ++, moderate effect; +++, large effect. 
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In an attempt to improve these results Suto et al designed a series of novel 3,4- 
dihydroisoquinolinones which were evaluated for radiopotentiation activity. 73 
Figure: 1.10.1.3,4-dihydroisoquinolinone as PADPRP inhibitors 
O 
8 
7/I NH 
R 
6\ 
5 
3,4-dihydroisoquinolinones 
The rational for the design of these novel inhibitors was based on the NAD+ binding 
domain of PADPRP. 3-Substituted benzamides are believed to bind to PADPRP in 
the same fashion as the nicotinamide moiety of NAD+. The authors proposed that 
the orientation of the amide was important in the association of the substrate / 
inhibitors with the enzyme. This has since been corroborated by comparison of 
PADPRP with glycohydrolases, which are other NAD+ dependent enzymes. Ab 
initio studies show that in free solution the amide of NAD+ is not restricted. 
However, on binding to the glycohydrolase enzyme the amide moiety preferentially 
adopts the anti conformation with respect to the 1,2-bond. 74,75 
NH2 
2IO 1 
2 
3 
RR 
anti syn 
There are two conformations the amide can adopt, either syn or anti to the 1,2- 
bond. The amide was constrained into one of these conformations by either of two 
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methods. The anti conformation was achieved via the introduction of an ethane 
bridge. This restriction produced a series of either 5- or 7- substituted 3,4- 
dihydroisoquinolinones. 73 
f 
00 
/ NH2 NH 
The second method involved introducing a substituent into the 2-position to form 
2,3-disubstituted benzamide analogues, thus, forcing the amide into a syn 
conformation (Figure: 1.10.2). 
On in vitro evaluation, the 2,3-disubstituted benzamide analogues were essentially 
completely inactive. Conversely, the dihydroisoquinolinones were exceptionally 
potent, with the 5-substituted dihydroisoquinolinones proving much more potent 
than nicotinamide. Interestingly, as the substituents were moved around the ring 
from 5- to 8-, the relative potencies decreased, with 8-hydroxy-3,4- 
dihydroxyisoquinolinone being the least active in the series, although still more 
active than nicotinamide. 
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Figure: 1.10.2. Benzamide analogues to determine the effects of substitution in the 2-position 
¶Z 
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vs 
R! 
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R=OH R' = CH2CH3, 
R' = CH2CHZCH3, 
R' = CH2CHCH2 
Previous work with PADPRP inhibitors, specifically 3-aminobenzamide, showed 
that inhibition of the enzyme during X-ray irradiation caused DNA damage, but 
that this damage was small and species specific. Studies showed that, after X-ray 
irradiation, some cells exhibited enhanced DNA damage if treated with 5- 
substituted isoquinolinones. 
a 
PD128763 
Further to this, Elliott et al developed the most potent published PADPRP inhibitor 
to date, PD 128763. This compound enhanced DNA damage in cells which had 
been exposed to X-rays. When examined in vivo, treatment of sarcoma with 
PD128763, in combination with radiotherapy, potentiated a 20 day tumour growth 
delay and caused 50% regression in tumour size with little side effects. 76 
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1.11. Structure-Activity Requirements for Optimal PADPRP Inhibition 
In reviewing reported studies regarding PADPRP inhibitors certain structural 
similarities have emerged, which suggest an optimal structure for specific and 
potent PADPRP inhibition. 
Planarity and aromaticity are pre-requisite structural features for potent PADPRP 
inhibition. Saturation of the ring system causes loss of activity, and 1,4- 
dihydrobenzamide analogues are also inactive. 
A carbonyl group, as part of the skeleton or attached to the aromatic system is 
desirable for inhibition. An increase in potency is observed if the carbonyl is part of 
an amide with at least one hydrogen present on the amide nitrogen. Inhibitory 
activity is considerably reduced on substitution of the C=O by C=S and completely 
lost when the amide is replaced by a carboxylic acid or a ketone. 
The conformation of the amide has a significant influence on potency with the anti 
conformation being more favourable for inhibition than the syn conformation, 
relative to the 1,2-bond in benzamide (Figure: 1.11.1. ). 
The removal of heteroatoms from the ring may improve potency, since benzamide 
is more potent than nicotinamide. 
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Figure 1.11.1 Minimal structure for potent PADPRP inhibition 
Substitution is tolerated at the 3-position but not at the 4-, 5- or 6- positions. 
PADPRP will tolerate groups at the 2- position provided the conformation of the 
amide remains unaffected. The presence of a non-cleavable bond at the 3-position 
increases inhibitory activity, as confirmed by Slama et al 67 This is particularly 
relevant if the proposed mechanism of action is correct. 
1.12. Method of PADPRP Assay 
It is not surprising that only general trends rather than specific conclusions can be 
drawn concerning the role of PADPRP in the cell and the structural requirements 
for its inhibition. The discrepancies between results may be due to the different cell 
lines used, the stage in the cell cycle in which exposure to the inhibitor occurred, 
timing of inhibitor addition and concentrations used. There are many different 
methods for screening for PADPRP inhibitors. The two more commonly used 
methods utilise permeabilised cells or pure enzyme. 
Therefore, it should be noted that quotation of reported inhibitory activities per se 
provides little information for comparison purposes. Table: 1.16. A. highlights the 
inter-assay differences when evaluating benzamide between some of the more 
commonly referenced papers. 
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Table: 1.12. A Inter-assay differences when evaluating benzamide 
author method of [NAD+] Expression of results 
ass! 
Banasik et al 64 pure enzyme 200 µM Inhibition as % of control 
ade-U-14C 92 % at [1.0 mmol 
Sims et al 62 permeabilised [adenine-3H] Inhibition as % of control 
cell 96 % at [2.0 mmol 
Purnell and isolated porcine 50 µM Inhibition as % of control 
Whish 56 thymus nuclei [adenine-3111 96 % at [50 
Cantoni et al 63 pure enzyme 111 p. M Inhibition as % of control 
32P 75 % at 50 gM] 
1.13. Summary 
As PADPRP is involved in the post incision repair of damaged DNA there are many 
theories as to its role in the cell, which include: 
PADPRP blocking sites of DNA damage, thus preventing the DNA polymerases 
from transcribing aberrant DNA. These stalling tactics may provide sufficient time 
for the DNA damage to be repaired, thus allowing the DNA polymerases a 
complete template for replication. Alternatively, PADPRP binding to the damaged 
site with subsequent automodification, could be an emergency signal to alert the cell 
to DNA damage. 
However, inhibition of PADPRP has been shown to retard DNA repair in DNA- 
damaged cells and concomitant dosing with a DNA damaging agent whilst 
inhibiting PADPRP has been shown to potentiate cell death. This potentiation of 
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cell death by PADPRP inhibition may provide a new potent resistant modifying 
agent to improve chemotherapy. 
This thesis details the research into novel inhibitors of Poly (adenine 
diphosphophate ribose) polymerase to potentiate DNA reactive drugs. The 
analogues detailed have been designed to achieve inhibition by min-king PADPRP's 
cofactor NAD+. 
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CHAPTER TWO 
Development of Analogues of 3-Hydroxybenzamide 
2.0 Introduction 
3-Substituted benzamides, particularly 3-aminobenzamide, are probably the most 
widely accepted PADPRP inhibitors, and benzamides appear to be good NADI 
mimics, binding to the nicotinamide region in the enzyme active site. There has 
been little research into other aspects of PADPRP binding including the effects of 
the ribose moiety and phosphate backbone mimics of NAD+ on potency. The work 
detailed in this chapter aims to elucidate the effects of larger hydrophobic groups 
and long chain spacer groups on inhibitory activity. 
Results and Discussion 
2.1. Synthesis of 3-Hydroxybenzamide 
3-Hydroxybenzamide was chosen as the parent compound because the phenolic OH 
provides a suitable 'handle' for the introduction of differing functionalities. As 3- 
hydroxybenzamide is not commercially available, an efficient preparation of this 
compound was required, and studies centred on a synthetic strategy beginning with 
3-hydroxybenzoic acid 1. 
Treatment of 1 with ethyl chloroformate and triethylamine gave the mixed 
anhydride and also protected the phenolic-OH. Subsequent addition of liquid 
ammonia at -78 OC afforded 3-hydroxybenzamide 2 in moderate yield, together with 
ethyl carbamate (urethane) 3, which is a carcinogen. 
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Figure: 2.1.1 Synthesis of 3-hydroxybenzamide 
1 
L CICOZCH2CH3 
NEt3; CH2C12 
ii. NH3 
2 
-i- H OCHZCH3 
3 
To circumvent this toxic by-product the mixed anhydride reaction was repeated 
using benzyl chloroformate. The major product, this time, was not the required 3- 
hydroxybenzamide but benzyl carbamate, with 1 remaining unchanged. As this 
procedure was problematic a simpler method was sought. 
H2N O 
benzyl carbamate 
One of the simplest methods for amide formation is via amination of an acid 
chloride. This approach cannot be applied to 1 directly owing to the presence of 
the phenolic OR Therefore, 1 was treated with acetic anhydride at 0 oC, yielding 
3-acetoxybenzoic acid 4, which was converted into the acid chloride by refluxing in 
thionyl chloride. Addition of aqueous ammonia furnished 3-hydroxybenzamide 2 
with concomitant deprotection of the phenol. This methodology was first 
attempted by Rhodes. 84 
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Figure: 2.1.2 Improved synthesis of 3-hydroxybenzamide 
1 
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Benzylation of 2 should provide information as to whether PADPRP tolerates large 
hydrophobic moieties. Suitably substituted phenyl groups may occupy the NADI 
binding site in a similar manner to the ribose group of NAD+. Base catalysed 
alkylation of 2 using potassium carbonate and benzyl bromide in refluxing 
acetonitrile furnished 3-benzyloxybenzamide 5 (BOB) in good yield (Figure: 2.2.1). 
Figure: 2.2.1 Synthesis of 3-benzyloxybenzamide 
C6H5CH2Br 
K2CO3 
CH3CN 
reflux, 16h, 65 % 
2 5 
A series of 3-benzyloxybenzamide analogues was prepared. The substituents 
included in this series were intended to determine the tolerance of PADPRP to 
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electronic effects, hydrophobicity, polarity and increasing chain length (Figure: 
2.2.2). 
Figure: 2.2.2 Benzyloxybenzamide analogues 
RCH2Br 
K2C03 
310 
CH3CN 
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2 
6R= 4-methoxybenzyl 
7R= 4-nitrobenzyl 
8R= 4-fluorobenzyl 
9R= 4-bromobenzyl 
10 R= 4-trifluoromethylbenzyl 
12 R= 3-nitrobenzyl 
13 R= 2-nitrobenzyl 
14 R=3,4-dioxymethylenebenzyl 
15 R= cinnamyl 
16 R= phenethyl 
11 R= 4-cyanobenzyl 
The introduction of a 4-methoxybenzyl and a 4-nitrobenzyl moiety was intended to 
determine the effects of strong electron donating and electron withdrawing groups, 
respectively, on inhibitory activity against PADPRP. Fluorine was introduced as it 
is a classical bioisostere for hydrogen, being of a similar size but with a different 
electronic effect. The bromo-substituent in 9 was introduced to increase the 
lipophilicity of the compound, which may increase diffusion across the cell 
membrane. Another bioisostere prepared was 4-cyano-BOB 11, as the nitrile 
moiety is a pseudohalide and would also be a precursor to a carboxylic acid group. 
By moving the substituents around the benzyl ring i. e. 2-nitro 13,3-nitro 12 and 4- 
nitro-BOB 7, any electron withdrawing effects would be determined. Similarly, the 
introduction of a strong electron donating group, for example in 3-(2,3 
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methylenedioxybenzyloxy)benzamide 14, may increase inhibitory activity. 
Phenethyl and cinnamyl derivatives (15 and 16) were intended to determine whether 
the chain length between the benzamide and phenyl moieties was important. The 
cinnamyl group also possesses an unsaturated bond which provides a useful handle 
for further'' functionalisation. 
Another interesting analogue required was 3-(4-azidobenzyloxy)benzamide 17. 
Azido groups are particularly important for photoaffinity labelling active drugs. 
They are also pseudohalides having similar physiochemical properties to bromo 
substituents. 
2.3 3-(4-Azidobenzyloxy)benzamide 
p-Toluidine served as the starting material for the synthesis of 4-azidobenzyl 
bromide as reported by Mornet et al. 79 p-Toluidine was diazotised and the azide 
introduced under standard conditions yielding 4-azidotoluene 18. Free radical 
bromination of 18, using N-bromosuccinimide with azoisobutyronitrile (AIBN) as 
the free radical initiator, afforded 4-azidobenzylbromide 19. Base catalysed 
alkylation of 2 with 19 yielded 3-(4-azidobenzyloxy)benzamide 17 in 55 % yield 
(Figure: 2.3.1). 
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Figure: 2.3.1 Preparation of 3-(4-azidobenzyloxy)benzamide 
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A major obstacle encountered during the determination of inhibitory activity was 
the low solubility of the analogues in physiological buffers. To overcome this 
problem two compounds were targeted, namely 4-amino-BOB 20 and 4-carboxy- 
BOB 21. The amino moiety in 20 is a polar group which may increase the solubility 
of the compound in aqueous systems, and preparation of the hydrochloride salt 
should be water soluble. Similarly, the 4-carboxylic acid analogue 21 should also 
exhibit an increased solubility either as the free acid or the sodium salt. 
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2.4.3-(4-Aminobenzyloxy) benzamide 
The standard procedure for the preparation of the BOB analogues was by 
nucleophilic displacement of a halide from the appropriate benzyl bromide as 
starting material. However, 3-(4-aminobenzyloxy) benzamide 20 could not be 
prepared from 4-aminobenzyl bromide because this compound is insufficiently 
stable. 4-Nitrobenzyl bromide had already been used to synthesise 3-(4- 
nitrobenzyloxy)benzamide 7, so the latter was used as a source for the amine 20. 
Reduction of 7 by hydrogenation was attempted, since the rate of nitro group 
reduction may be more rapid than the rate of debenzylation. Compound 7 was 
added to a palladium-carbon catalyst suspended in methanol under a hydrogen 
atmosphere, and the reaction monitored by TLC. Although reduction of the nitro 
group occurred, so did debenzylation and the isolated products were 2 and p- 
toluidine. 
The reaction was repeated using a microhydrogenator, which enabled the reduction 
to be conducted with a defined volume of gas. 80 One equivalent of hydrogen was 
taken up and a mixture of products was obtained. It is likely that the rate of 
debenzylation may be enhanced by the presence of the electron withdrawing 4-nitro 
group, so that it occurs as rapidly, if not faster than reduction of the nitro group. 
Since this method was unsuccessful further methods were sought. 
Amino groups can also be introduced by the preferential reduction of azides under 
very mild conditions, therefore 4-azidobenzyloxybenzamide 17 was utilised. A well 
documented and mild procedure for the reduction of azides is the Staudinger 
reaction. 81 The Staudinger reaction utilises the nucleophilicity of 
triphenylphosphine to convert the azide to an iminophosphorane, which 
decomposes on treatment with water to form the amino group and 
triphenylphosphine oxide as a by-product. 
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Figure: 2.4.1. Mechanism of the Staudinger reduction 
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This approach was utilised for the reduction of 17 in anhydrous ether. On work up 
there was no product isolated in the organic phase, but trace amounts of product 
were found in the aqueous phase. The reaction was repeated, but this time was 
quenched with 0.1 M aqueous HCl in order to form the hydrochloride salt of the 
required amine. Although 22 was isolated, the yield was very low, and an 
alternative approach was therefore investigated. 
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Figure: 2.4.2. Synthesis of 3-(4-aminobenzyloxy)benzamide hydrochloride 
TPP 
Et20; HC1(aq) 
17 22 
A method reported by Rosen et al was the reduction of an azide with subsequent 
acylation of the resulting amino group. 82 Compound 17 was dissolved in an excess 
of thioacetic acid and stirred at ambient temperature until the reaction was 
complete. Removal of the excess of thioacetic acid yielded 3-(4-N- 
acetylaminobenzyloxy)benzamide 23 (Figure 2.4.3). 
Figure: 2.4.3. Synthesis of 3-(4-N acetylaminobenzyloay)benzamide 
CH3COSH 
lip, 
96h 
64% 
17 23 
Whilst this method furnished 23 in moderate yield the reaction was slow and 
deprotection of the N-acetylamino functionality to form the free amine species 
added yet another step to the synthetic pathway. 
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An alternative procedure examined was the mild and selective reduction of azides 
by dithiothreitol (DTT)83. A possible mechanism for this reduction involves 
intramolecular attack by the S thiol to yield a dithiane by-product which was easily 
removed (Figure: 2.4.5). 
Figure: 2.4.4. Mechanism of azide reduction by dithiothreitol 
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Figure: 2.4.5. Synthesis of 3-(4-aminobenzyloxy)benzamide 
DTT, NEt3 
CH3OH 
2h 
55% 
17 20 
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2.5.3-(4-Carboxybenzyloxy)benzamide 
4-Chloromethylbenzoic acid was the starting material used. Acid catalysed 
esterification of 4-chloromethylbenzoic acid in refluxing methanol furnished methyl 
(4-chloromethyl)benzoate 24. The methyl ester was required for increased 
solubility and easier manipulation. Compound 24 was used for the base catalysed 
alkylation of 2 to yield 3-(4-carboxymethylbenzyloxy)benzamide 25 (Figure: 2.5.1). 
Figure: 2.5.1. Synthesis of 3-(4-carboxymethylbenzyloxy)benzamide 
CI 
CH3OH / H+ 
reflux 
99% 
OOH 
C1 
2 
K2CO3 
CH3CN 
55% 
OOCH3 
24 25 
OOCH3 
Stirring 25 in a solution of 0.1 M sodium hydroxide hydrolysed the methyl ester 
affording the sodium salt, and subsequent acidification to pH 3 yielded the free acid 
21 (Figure: 2.5.2). 
Figure: 2.5.2. Synthesis of 3-(4-carboxybenzyloxy)benzamide 
25 
OOCH3 i. NaOH 
CH3OH / H2O 
ii. H+ to pH 3 
21 
COOH 
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2.6 3-Alkoxybenzamide Analogues 
Novel PADPRP inhibitors designed to mimic the phosphate backbone and adenosyl 
group of NAD have previously been prepared. These inhibitors encompassed a 
series of 3-(bromoalkoxy)benzamide and 3-(purinylalkoxy)benzamide analogues. 84 
When examined in vitro these analogues exhibited some inhibitory activity, but 
whether this potency was determined by chain length, or by the moieties attached, 
or a combination of both was not ascertained. To clarify this, a simple homologous 
series of inhibitors without any pendant functional groups was required to 
determine the effect of chain length on potency. 
0 
" N'12 
kBr 
(CH2)n 
n=5,8,12 
3-(bromoalkoxy)benzamides 
N R 
INr/ 
(CH)n 
n=5,8,12 
R= CI, NH2 
3 -(purinylalkoxy)benzamides 
The homologous series included analogues ranging from butyl to octyl. The butyl 
26 and pentyl 27 derivatives were synthesised via base catalysed alkylation of 2 
with the corresponding alkyl iodides (Figure: 2.6.1). 
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Figure: 2.6.1. Synthesis of 3-butyl and 3-pentyloxybenzamide 
I (CH2)n CH3 
K2CO3 
CH3CN 
ref lux 
26 n=3 butyl 
27 n=4 pentyl 
The hexyl 28, heptyl 29 and octyl 30 derivatives were prepared, by Day (University 
of Newcastle upon Tyne, unpublished results), from the corresponding mesylates 
because the respective alkyl halides were not commercially available. The mesylates 
were prepared by treating the respective alcohols with methanesulphonyl chloride in 
the presence of triethylamine. Subsequent base catalysed alkylation of 2 with the 
appropriate mesylate afforded the corresponding alkoxybenzamide (Figure: 2.6.2). 
Figure: 2.6.2. General synthesis of 3-hexyloxybenzamide, 3-heptyloxybenzamide 
and 3-octyloxybenzamide analogues 
CH3S03(CH2)n CH3 
K2C03 
CH3CN 
reflex 
28 n=5 hexyl 
29 n=6 heptyl 
30 n=7 octyl 
(CH2) CH3 
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CHAPTER THREE 
Development of 2-Substituted Derivatives of 3-Hydroxybenzamide 
3.0 Introduction 
Suto et al proposed that the conformation of the amide group of 3-substituted 
benzamides was partially responsible for potency, and that the active conformation 
has the carbonyl bond anti to the 1,2 bond. 73 The most potent PADPRP inhibitors 
reported contain an amide conformationally restricted in a bicyclic system, notably 
PD128763, which has potent activity both in vitro and in vivo. 76 
This chapter details research into an alternative means of restraining the amide via a 
hydrogen bond between the amide and an electron-donating moiety in the 2- 
position, thus producing effective PADPRP inhibitors. 
Results and Discussion 
3.1. Benzoxazole-4-carboxamides 
Certain benzoxazole derivatives are of biological interest owing to their anti- 
inflammatory activity, the most notable example being benoxaprofen. Benzoxazole- 
containing natural products of biological interest include Calcinomycin. 87 
51 
NHCH3 
OH 
Calcinomycin Benoxaprofen 
There are various methods for the preparation of benzoxazole, and these have been 
the subject of many reviews, but o-amino phenol is one of the most versatile starting 
materials. 88-95 
Figure: 3.1.1. General synthesis of benzoxazoles 
OH 
NH2 
RCOOH 
RCOC1 
(RCO)20 
RCONH2 
RCHO / Pb(OAc)4 
RCN 
RC(OR')=NH 
0 
-' \/R 
In most reported procedures the products possess a substituent in the 5-position of 
the phenyl ring. Recently, Goldstein and Dambek detailed the synthesis of a series 
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of methyl benzoxazole-4-carboxylates, as intermediates for natural products, 
starting from 3-hydroxyanthranilic acid 31.96 
YH OH 
NHz 
31 32 
Whilst 31 is commercially available, the cost of the quantity required to complete a 
series of inhibitors was prohibitive. Therefore, the immediate precursor, 3-hydroxy- 
2-nitrobenzoic acid 32, which is considerably cheaper, was used as the starting 
material. 
3.2. Starting Material 
The carboxylic acid group of 3-hydroxy-2-nitrobenzoic acid 32 was protected as 
the methyl ester 33 by acid catalysed-esterification, since 32 is only soluble in polar 
solvents such as methanol or DMSO, thus causing manipulation problems. The 
ester was also prepared in order to prevent any unwanted side reactions occurring 
during further steps. Catalytic hydrogenation of the nitro group afforded methyl 2- 
amino-3-hydroxybenzoate 34. 
Figure: 3.2.1 Preparation of methyl-2-amino-3-hydroxybenzoate; general starting material for 
benzoxazole synthesis 
O 
NO 
H 
32 
YH -OH CH3OH 
+ reflux 
NOZ H 98% 
33 
Pd /C (cat) 
H2 CH3OH 
100% 
34 
53 
3.3.2-Methylbenzoxazole-4-carboxamide 
The first analogue targeted was 2-methylbenzoxazole-4-carboxamide. Initial 
studies centred on the use of acid chlorides to form the oxazole moiety in a one pot 
procedure. 96 Treatment of 34 with acetyl chloride, triethylamine and the acid 
catalyst pyridinium p-toluenesulfonate (PPTS) in refluxing m-xylene afforded a 
small amount of the required methyl 2-methylbenzoxazole carboxylate 35, which 
was isolated by column chromatography. As this procedure was low yielding 
another route was explored. 
Figure: 3.3.1 Preparation of methyl 2-methylbenzoxazole-4-carboxylate 
0 
OCH3 
NH 2 
H 
CH3COCI 
NEt3 
PPTS 
m-xylene 
reflar, 6% 
O 
OCHS 
N 
CH3 
34 35 
An alternative method for the production of benzoxazoles is from the reaction of 
aminophenols with iminoethers. The formation of iminoethers from nitriles is 
known as the Pinner reaction and has been well documented. 87 Treatment of the 
nitrile with an alcohol in the presence of hydrogen chloride affords the HCl salt of 
the iminoether. Thus, ethyl acetimidate hydrochloride 36 was obtained by acid 
catalysed ethanolysis of acetonitrile under anhydrous conditions at 0 0C. 
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Figure: 3.3.2. Pinner synthesis to form ethyl acetimidate hydrochloride 
(I NRHCI 
H3C-C=N+H 
H3C OCHZCH3 
Hoeoý'CH2CH3 36 
v 
A model study for the preparation of 2-methylbenzoxazole was performed using 36. 
2-Aminophenol was refluxed with imidate 36 in anhydrous ethanol for 5h. The dry 
conditions are important as imidates are susceptible to hydrolysis to the 
corresponding amide. The reaction between the aminophenol and the imidate to 
create the oxazole moiety is dependent on the electrophilicity of the carbonyl group 
as the initial step is attack from the amino group at the electrophilic centre. 
Subsequent ring closure followed by dehydration afforded 2-methylbenzoxazole 37 
cleanly and in good yield. 
Figure: 3.3.3. Model studies for benzoxazole formation 
cOH 
NH2 
36 
CH3CH2OH 
reflux 
ao 
/ CH3 
37 
Encouraged by this success, imidate 36 was refluxed in anhydrous ethanol with 34 
until the reaction was complete. The product, methyl 2-methylbenzoxazole-4- 
carboxylate 35 was again isolated cleanly and in good yield. 
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Figure: 3.3.4. Preparation of methyl 2-methylbenzoxazole-4-carboxylate 
0 
OCHS 
MIZ 
H 
34 
36 
CH3CH2OH 
reflux 
35 
Attempts at the preparation of the 2-methylbenzoxazole-4-carboxamide by the 
direct reaction of ammonia with 35 at high pressure were unsuccessful. Under 
these reaction conditions an interesting rearrangement took place, resulting in the 
formation of another series of potent PADPRP inhibitors (see Chapter 4). 
Figure: 3.3.5. Attempted preparation of 2-methylbenzoxazole-4-carboxamide 
35 
NH3 (liq) 
20 bar pressure 
55 °C 
39 
69 
56 
An alternative approach involved hydrolysis of the ester to the acid, followed by 
conversion into the acid chloride, which when treated with ammonia should afford 
the carboxamide. 
Base catalysed hydrolysis of carboxylate 35 with 0.1 M sodium hydroxide at 40 °C 
gave the sodium salt as expected, but acidification to liberate the free acid occurred 
with concomitant ring opening. This ring opening side reaction was surprising since 
the C2 position of benzoxazoles is not especially susceptible to nucleophilic attack. 
However, in strong acid solution protonation of the oxazole moiety presumably 
facilitates hydrolysis, which leads to ring opening. 
Figure: 3.3.6. Formation of 2-methylbenzoxazole carboxylic acid 
0.1M NaOH 
40°C 
HCI 
\ NaOH 
%021 1 ONa 
N 
Oý 
CH3 
HCI/H20 
H 
.. / 
\ 
H 
On a small scale, formation of the ring opened product could be reduced by cooling 
the reagents and solvents to 4 °C. On a larger scale, however, ring opening still 
occurred and as a result this method required further optimisation. 
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To avoid the ring opening side reaction the ester 35 was hydrolysed with one 
equivalent of sodium hydroxide. The salt obtained was isolated and redissolved in 
water with cooling to 4 °C. Dropwise acidification using 0.05 M hydrochloric acid 
was closely monitored (pH meter) and an extraction was performed with cold 
solvent with each pH unit change observed. The optimum pH for formation of the 
free acid, without ring opening, was found to be 4.5. By this approach 2- 
methylbenzoxazole-4-carboxylic acid 38 was isolated in a reasonable yield. 
Figure: 3.3.7. Preparation of 2-methylbenzoxazole-4-carboxylic acid 
0.05 M HCl 
pH = 4.5 
4 oC 
38 
The acid 38 was converted into the amide via aminolysis of the corresponding acid 
chloride and the 2-methylbenzoxazole-4-carboxamide 39 product was purified by 
recrystallisation from ethyl acetate/petrol. 
Figure: 3.3.8. Synthesis of 2-methylbenzoxazole-4-carboxamide 
L SOC12 
DMF 
THE 
ii NH3 (ay) 
38 39 
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A comparison of the spectroscopic data for 2-methylbenzoxazole-4-carboxamide 39 
and the rearranged product 8-hydroxy-2-methylquinazolinone 69 are highly 
informative. In the 1H NMR of benzoxazole 39 (Figure: 3.3.9) H7 was shifted 
downfield from H6, whereas in the quinazolinone spectrum (Figure: 3.3.10) H7 is 
upfield from H6, which may be attributed to electron donation from the hydroxy 
group. In 13C NMR of the benzoxazole carboxamide 34, the carbonyl carbon 
resonated at 174.5 ppm (Figure: 3.3.11), whereas the quinazolinone carbonyl 
carbon 69, resonated at 162.1 ppm (Figure: 3.3.12). 
Substantial evidence to distinguish the isomers was obtained by measuring their UV 
spectra in neutral and basic solutions. The differences in the UV spectra for 
benzoxazole 39 before, and after addition of the base were minimal (Figure: 
3.3.13). Conversely, for quinazolinone 69 there was a significant shift to a longer 
wavelength on addition of base, corresponding to increased conjugation expected 
on deprotonation of the phenol (Figure: 3.3.14). 
The final, and conclusive analysis, which confirmed the respective structures, was 
X-ray crystallography. The crystal structure of 2-methylbenzoxazole-4- 
carboxamide (Figure: 3.3.15) highlights the presence of the H-bond between N(1) 
and H(2a), with the bond being 2.09 A in length. This was considerably longer than 
a normal N-H bond (ca 1.05 A in length), 97 and is typical of a hydrogen bond. 
Once the synthesis of amide 39 had been optimised, the benzoxazole carboxylic acid 
38 proved a suitable precursor for another interesting analogue, namely 2- 
methylbenzoxazole-4-N-methylcarboxamide 40. This compound may provide an 
insight as to whether PADPRP is tolerant to substitution of the amide protons with 
other groups. 2-Methylbenzoxazole-4-N methylcarboxamide 40 was prepared from 
the acid chloride of 38 by treatment with methylamine (Figure: 3.3.16). 
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Figure: 3.3.16. Synthesis of 2-methyl benzoxazole-4-N methylcarboxamide 
i SOC12 
DMF 
THE 
ü CH3NH2 
(33 % in EtOH) 
38 40 
3.4.2-Phenylbenzoxazole-4-carboxamide 
Repeating the Pinner reaction with benzonitrile in acidic ethanol afforded the ethyl 
benzimidate hydrochloride salt 41 . 
Figure: 3.4.1. Synthesis of ethyl benzimidate hydrochloride 
CN CH3CH2OH 
31- 
HC1 OOC 
NHZ+cr 
OCH2CH3 
41 
Heating aminophenol 34 and imidate 41 in ethanol under reflux for 16 h afforded 
methyl 2-phenylbenzoxazole-4-carboxylate 42. The ester was stirred at ambient 
temperature in aqueous ammonia to produce the amide 43 with no rearrangement 
to the quinazolinone. The stability observed could possibly be due to the steric bulk 
of the phenyl ring restricting access of ammonia to the C2 centre. Alternatively, or 
additionally, conjugation of the phenyl with the benzoxazole system may reduce the 
electrophilicity of the C2 centre. 
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Figure: 3.3.13 UV spectra for 2-methylbenzoxazole-4-carboxamide 39 (ethanol) 
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Figure: 3.3.14 W spectra of 8-Hydroxyquinazolin-4[3H]-one 69 (ethanol) 
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Figure: 3.3.15. X-ray crystal structurc of 2-mcth}, Ibcnzoxazolc-4-carboxamidc 
(crystallographic data in Appendix 1) 
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Figure: 3.4.2. Synthesis of 2-phenylbenzoxazole-4-carboxamide 
NH3 (aq) 
CH30H 
42 43 
3.5.2-tert-Butylbenzoxazole-4-carboxamide 
Unfortunately, the Pinner reaction was unsuccessful with tbutyronitrile, as the steric 
effect of the butyl group will reduce the rate of alcohol attack on the nitrile carbon. 
Therefore, the alternative acid chloride method was utilised. The 
hydroxyanthranilic ester 34 was refluxed with tbutylcarbonyl chloride, triethylamine 
and PPTS in m-xylene for 16 h, and the product, methyl 2-tbutylbenzoxazole-4- 
carboxylate 44, was isolated by column chromatography. Conversion to the amide 
45 was again achieved by stirring ester 44 in aqueous ammonia at ambient 
temperature. The C2 centre was again stabilised in a manner comparable to the 
phenyl derivative. The steric effect of the tbutyl group restricting access of 
ammonia to the C2 centre stopped any rearrangement or ring opening side reactions 
occuring. 
68 
Figure: 3.5.1 Synthesis of 2 tbutylbenzoxazole-4-carboxamide 
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3.6. Substituted phenylbenzoxazole-4-carboxamides 
The two analogues required initially were 2-(4-methoxyphenyl)benzoxazole-4- 
carboxamide and 2-(4-nitrophenyl)benzoxazole-4-carboxamide since the 4-nitro and 
4-methoxy moieties will indicate whether electronic effects cause a difference in 
potency. Initial attempts at preparing the respective imidates by the Pinner 
procedure were unfruitful. A second method reported by Schaefer and Peters, 
details the preparation of imidates from nitriles via base catalysis. 98 Although this 
method details the synthesis of a wide variety of aliphatic and aromatic imidates, 
those nitriles which have electronegative groups react at a faster rate. This is not 
surprising considering the enhanced electrophilicity at the nitrile carbon. 
Unfortunately, no product was isolated when this method was attempted. 
Whilst the method reported by Goldstein and Dambek worked, the yields were poor 
and optimisation of this method was necessary. Although the preparation of 
benzoxazole carboxylates involved a one pot reaction, the mixture of products 
obtained suggested that the reaction would proceed more efficiently if performed 
stepwise. 
The first step involved acylation of the nitrogen with the substituted acid chloride, 
and initial attempts yielded only 50 % of the required product. This was possibly 
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due to the amine becoming protonated as the reaction progressed. Addition of 
pyridine as a proton acceptor and acylation catalyst, afforded the amides 46 and 47 
in excellent yield, particularly if the acid chloride and pyridine were stirred together 
before addition of the aminophenol starting material 34. 
Figure: 3.6.1. General synthesis of methyl2-(4-substitutedbenzoylamino)-3-hydroxybenzoate 
0 
OCHS 
NH2 
H 
34 
RC6H40001 
pyridine 
310. 
THE 
46 R=N02 
47 R= OCHS 
R 
Acid catalysed cyclisation to the oxazole moiety was achieved by refluxing the 
methyl-2-(4-substitutedbenzoylamino)-3-hydroxybenzoates 46 and 47 with 
triethylamine and PPTS in m-xylene for 16 h, the products being isolated by column 
chromatography. 
Since conversion of ester 35 to amide 39 had proved successful, this method was 
again employed for compounds 48 and 49 which were each hydrolysed under basic 
conditions, and the reaction was acidified to pH = 4.5. This yielded the free acid 
51, but unfortunately ring opening of the oxazole occurred with ester 48 hence 
compounds 50 and 52 were not completed. Aminolysis of the acid chloride from 51 
yielded 2-(4-methoxyphenyl)benzoxazole-4-carboxylate 53. 
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Figure: 3.6.2. Synthesis of methyl 2 (4-substituted phenyl)benzoxazole carboxylate derivatives 
13 
PPTS 
m-xylene 
reflux 
16h 
R 
46 R= N02 
47 R= OCHS 
48 R= N02 
49 R= OCHS 
Figure: 3.6.3. Synthesis of 2 (4-substituted phenyl)benzoxazole-4-carboxamide derivatives 
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71 
3.7.2-(4-Carboxyphenyl)benzoxazole-4-carboxamide 
Solubility problems are frequently encountered during biological evaluation, 
particularly with some of the more hydrophobic analogues. Therefore, 2-(4- 
carboxylphenyl)benzoxazole-4-carboxamide was required since this should be a 
water soluble benzoxazolecarboxamide analogue. Preparation of this analogue 
began from the usual hydroxyanthranilic ester starting material 34. The acid 
chloride required for the acylation step was prepared by stirring 
monomethylterephthalic acid in thionyl chloride. Acylation of methyl 2-amino-3- 
hydroxybenzoate 34 with monomethylterephthalic acid chloride afforded methyl 2- 
(4-methylcarboxybenzoylamino)-3-hydroxybenzoate 54, which was subsequently 
cyclised to methyl-2-(4-methylcarboxyphenyl)benzoxazole-4-carboxylate 55. 
Figure: 3.7.1. Preparation of methyl 2-(4-methycarboayphenyl)benzoxazole4-carboxylate 
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1H NMR analysis of the diester 55 showed the two methyl groups to be marginally 
different, about 0.2 ppm apart. Selective deprotection of the diester 55 was 
required, as it was necessary to prepare the 4-carboxamide before conversion of the 
phenyl ester to the free acid, in order to prevent formation of the diamide. 
Hydrolysis of 55 using sodium hydroxide yielded a salt which on acidification gave 
the diacid. Alternative methods tried included the use of zinc chloride. 
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Zinc chloride should act as a Lewis acid and coordinate to the ester and the oxazole 
nitrogen, thus enhancing the electrophilicity of the carbonyl and facilitating 
hydrolysis. This reaction was attempted at a variety of pH's without success, hence 
an alternative route to selective deprotection was investigated, where the amide was 
introduced initially, thus avoiding the need for selective deprotection. 
The alternative procedure began by protecting the phenolic OH of 3-hydroxy-2- 
nitrobenzoic acid as an acetoxy group to afford 57.3-Hydroxy-2-nitrobenzamide 
58 was prepared via aminolysis of the ibutyl mixed anhydride and hydrogenation of 
58, using a carbon on palladium catalyst under a hydrogen atmosphere, yielded 2- 
amino-3-hydroxybenzamide 59 in excellent yield. 
Figure: 3.7.2. Attempted selective deprotection of the diester 
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I 
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55 56 
Acylation of 2-amino-3-hydroxybenzamide 59 with monomethylterephthalic acid 
chloride afforded 3-hydroxy-2-(4-carboxymethylbenzoyl)aminobenzamide 60. 
Cyclisation to the target benzoxazole has proven to be problematical, and 
insufficient time remained to enable further investigation of this reaction. 
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Figure: 3.7.4. Synthesis of 2-(4-carboayphenyl)benzoxazole-4-carboxylate 
1. 11. 
58 
iii. 
vi. iv. 
W2 
H 
O 
COOCH3 
60 59 
61 
Reagents: i. Ac20, NaOH, 0 0C, [ H+ work up]; ii. 'BuOCOCI, NEt3, THF, 0 OC; 
NH3 (aq. ); iii. Pd/C cat., H2, CH3OH; iv CH3O00C6H4COCI, pyridine, THF; 
v. NEt3, PPTS, m-xylene, reflux; vi ester hydrolysis. 
3.8.2,3-Methylenedioxybenzamide 
2,3-Methylenedioxybenzamide was required on the basis that the oxygen in the 2- 
position may act as an electron donor, thus, increasing the negativity at the carbonyl 
oxygen and enhancing inhibitory activity. Also it may form an intramolecular 
hydrogen bond with an amide proton. Since the first reported methylation of 
catechol by Fittig and Remson99 there have been numerous alternative methods 
published, 100,101 including the use of strong bases in aprotic solvents with 
bronze, 102 or cupric oxide103 catalysts to enhance reaction rates. Phase transfer 
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catalysis of catechols may provide a mild and high yielding method for alkylation, 
but reaction times may be slow. 104 
Initial attempts at the synthesis of 2,3-methylenedioxybenzamide using several of 
the above procedures were unsuccessful; in most cases the starting material 
remained unchanged after extended reaction at high temperatures. There was some 
concern as to the detrimental affects of a carboxylic acid ortho to the reacting 
moiety, because the electron withdrawing properties of the carboxylic acid 
deactivates the adjacent hydroxy group, decreasing the nucleophilicity of the anion, 
thus slowing the rate of reaction. 
However, Perkins and Trikojus reported a simple method for the preparation of 63 
by refluxing diiodomethane and potassium hydroxide with 2,3-dihydroxybenzoic 
acid in methanol/water. 105 The corresponding acid chloride was prepared by 
stirring 62 with thionyl chloride; subsequent addition of aqueous ammonia 
furnishing the target compound 63 in excellent yield. 
Figure: 3.8.1 Synthesis of 2,3-dioxymethylenebenzamide 
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ii. NH3 (aq) 
63 
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3.9.2-Fluoro-3-hydroxybenzamide 
The synthesis of 2-fluoro-3-hydroxybenzamide 68 was attempted as fluorine is a 
strongly electronegative species which forms hydrogen bonds readily. Therefore, 
fluorine substituted in the 2-position of 3-hydroxybenzamide should also constrain 
the amide into the anti conformation via an intramolecular hydrogen bond. A well 
documented method for preparing aromatic fluorides from aryl amines is the Balz- 
Schiemann decomposition of a diazonium tetrafluoroborate salt. 106,107 However, 
certain substituents are known to affect adversely the decomposition of the 
diazonium species, (particularly hydroxy and carboxy moieties). Consequently, 3- 
methoxy-2-nitrobenzoic acid was used as the starting material, with the methoxy 
group being deprotected as the final step. 3-Methoxy-2-nitrobenzoic acid was 
converted into the amide 64 by aminolysis of the corresponding acid chloride. 
Catalytic reduction of 64 yielded 2-amino-3-methoxybenzamide 65. Diazotisation 
of 65 in a solution of fluoroboric acid with sodium nitrite at 0 OC produced the 
tetrafluoroborate salt 66. Decomposition of this intermediate should have given the 
fluoro species 67, but instead afforded in a complex mixture of reaction products 
which were inseparable by preparative TLC. Further attempts at decomposing 66 
in different fluorinated solvents such as trifluoroethanol were unsuccessful. 
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Figure: 3.9.1. Attempted synthesis of 2-fluoro-3-hydroxybenzamide 
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CHAPTER FOUR 
Rearrangement of Benzoxazole-4-carboxamides to 8- 
Hyd roxyquinazolin-4-ones 
4.0 Introduction 
Certain quinazolinones have been shown to have important cancer 
chemotherapeutic properties. The most notable is CB3717, which has potent 
inhibitory activity against the enzyme thymidylate synthase (TS). 109,110 TS uses 
5,10-methylenetetrahydrofolic acid as a cofactor to catalyse the conversion of 
deoxyuridine monophosphate to deoxythymidylate by reductive methylation. 
H 
5,10-Methylenetetrahydrofolic acid 
O 
--ýN 
GOOH 
-H 
H3C' N 
C 
CB 3717 
)OH 
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TS inhibition can cause a block in the de novo synthesis of deoxythymidylate which, 
in the absence of exogenous thymine, leads to a'thymine-less cell death'. 
There are many known methods for the preparation of quinazolinones, 111-115 
some of which are summarised in Figure 4.0.1. 
Figure: 4.0.1 General synthesis of quinazolinones 
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A general approach to the preparation if quinazolinones begins with an ortho 
substituted aromatic ring. In examples a, b, and c, (Figure: 4.0.1) acylation of the 
amino group followed by cyclisation formed the quinazolinone skeleton. These 
methods are the most versatile and widely used ways of preparing quinazolinone 
derivatives. 111,112 However, there are more elegant, although not necessarily more 
efficient ways, of preparing these compounds. Example d (Figure: 4.0.1) shows the 
catalytic reductive N-heterocyclisation of nitrobenzoyl amides under a carbon 
monoxide atmosphere to form quinazolinones. 113 Whilst this is one of the first 
ruthenium-catalysed syntheses of quinazolinones, the use of an expensive catalyst, 
and with only moderate yields, makes this a less versatile approach to these 
derivatives-114 Conversely, example e (Figure: 4.0.1) exhibits an efficient high 
yielding synthesis of quinazolinones via an intramolecular aza-Wittig reaction. 115 
Results and Discussion 
4.1. The Rearrangement 
The rearrangement of benzoxazole-4-carboxamide to 8-hydroxyquinazolin-4-[3H]- 
one was chanced upon under reaction conditions employed to form an amide from 
an ester. The rearrangement was first observed when methyl 2-methylbenzoxazole- 
4-carboxylate 42 was reacted with ammonia under high pressure. Under these 
conditions the product isolated was 8-hydroxy-2-methylquinazolin-4[3H]-one 69 
rather than the expected benzoxazole-4-carboxamide. The structure of 8- 
hydroxyquinazolin-4-[3H]-one was confirmed by X-ray crystallography. 
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Figure: 4.1.1. X-ray crystal structure of 8-hydroxy-2-methylquinazolin-t[3F] -one 
(crystallographic data in appendix 2) 
Z 
Z- 
0 
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Figure: 4.1.2 Formation of 8-hydroxy-2-methylquinazolin-4[3HI-one from methyl 2- 
methylbenzoxazole-4-carboxylate 
NH3 (liquid) 
30 
20 bar pressure 
55 OC 
42 69 
Similar conditions were employed for the preparation of 8-hydroxy-2-(4- 
nitrophenyl)quinazolin-4 [3H] -one 70 from methyl 2-(4-nitrophenyl)benzoxazole-4- 
carboxylate 57. 
Figure: 4.1.3 Preparation of 8-hydroxy-2-(4-nitrophenyl)quinazolin-4[3H]-one. 
NH3 (liquid) 
20 bar pressure 
55 OC 
70 
57 
A further example of the rearrangement, but under milder reaction conditions, was 
the preparation of 8-hydroxy-2-methyl-3-methylquinazolin-4[3H]-one 71 from 
methyl-2-methylbenzoxazole-4-carboxylate 42 by stirring with methylamine (33 % 
in ethanol) at ambient temperature. 
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Figure: 4.1.4. Preparation of 8-hydroxy-2-methyl-3-methylquinazolin-4[3H]-one 
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71 
Treatment of methyl 2-(4-methoxyphenyl)benzoxazole-4-carboxylate 58 with 
ammonia under pressure did not afford the quinazolinone. The product isolated 
was the benzoxazole-4-carboxamide 54. 
Figure: 4.1.5. Preparation of 2-(4-methoxyphenyl)benzoxazole-4-carboxamide 
58 
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20 bar pressure 
55 OC 
CH3 
54 
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4.2 Putative mechanism of benzoxazole rearrangement 
The probable mechanism of the benzoxazole rearrangement may be deduced from 
the few examples cited. The rearrangement depends upon the electrophilicity of the 
C2 centre. That is, if the substituent in the 2-position is a good electron donor or 
sterically bulky the rearrangement does not occur. However, if the C2 carbon is 
relatively electron deficient then the rearrangement may take place. 
In compounds 69 and 70 the rearrangements took place at relatively high pressure. 
The formation of 71, however, was at ambient temperature with methylamine as the 
nucleophile. The ease with which this rearrangement occurred was not unexpected 
considering that methylamine is a stronger nucleophile than ammonia. 
Therefore, the initial phase of the rearrangement may entail nucleophilic attack at 
the C2 centre to form a ring opened intermediate, analogous to the acid catalysed 
ring opening of benzoxazoles discussed in Chapter 3 (Figure: 4.2.1). 
Figure: 4.2.1 Postulated mechanism of ring opening 
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Ring closure may occur in either of two ways: 
A. attack from the amidine nitrogen to the carbonyl; 
B. attack from the amide to the iminium centre. 
In either case the mechanism may be facilitated by proton transfer (Figure: 4.2.2). 
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Figure: 4.2.2. Postulated mechanisms of ring closure 
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In the proposed mechanisms it was assumed that aminolysis of the carboxylic ester 
occurred before ring opening. Although likely, this may not be the case, and the 
unchanged ester may participate in the rearrangement. If this is so then there can 
only be one mechanism of ring closure, i. e. attack from the amidine nitrogen onto 
the carbonyl with subsequent loss of methanol. 
Figure: 4.2.3. Alternative mechanism for the rearrangement 
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CHAPTER FIVE 
5.0 Enzyme Inhibition Studies 
5.0.1. Permeabilised Cell Assay 
The analogues were evaluated using a permeabilised cell assay by the author and 
Bowman (Cancer Research Unit, Newcastle upon Tyne). The cell membrane was 
permeabilised using hypoxic shock and cold conditions. The permeabilised cells 
were added to a tube containing a solution of drug, NAD+ cocktail and 
oligonucleotide, and incubated, for exactly 5 mins. 116,117 Inhibitor activity was 
determined by measuring the degree of 32P incorporation into an acid insoluble 
pellet. The degree of inhibition was calculated as a percentage of control. 
5.1. Inhibition of PADPRP by Benzyloxybenzamide Analogues 
3-Hydroxybenzamide 2 has been used as a reference system throughout the in vitro 
evaluation. There was no decrease in inhibitory activity when benzyloxybenzamide 
5 was tested in the permeabilised cell assay which suggested that PADPRP was 
tolerant to larger hydrophobic moieties (Table 5.1. A. ). In general, the analogues 
with electron donating groups have exhibited marginally increased inhibitory 
activity, for example 6 and 14. Conversely analogues with electron withdrawing 
substituents were less active, see 7,10 and 12. These results may be useful when 
elaborating more active PADPRP inhibitors, for example 8-hydroxyquinazolinones. 
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Table: 5.1. A. Percentage PADPRP inhibition by benzyloaybenzamide analogues 
No R 
(position) 
compound % inhibition 
at 10 M 
3 - 3-h dro benzamide 35 
5 (4) H 3-ben lo benzamide 36 
6 (4) OCH 3- 4-metho be lo benzamide 60 
7 (4) NO 3-(4- itrobenlox benzamide 26 
8 (4) F 3- 4-fluorobe lo benzamide 14 
9 (4) Br 3- 4-bromoben lo benzamide 26 
10 (4) CF3 3-(4-trifluoromethyl 
be lox benzamide 
3 
11 (4) CN 3- 4-c anobe lox benzamide 23 
12 (3) NO 3- 3-nitrobe lox benzamide 12 
13 (2) NO 3- 2-nitrobe lo benzamide insoluble 
14 (3,4) 
OCH O 
3-(3,4-dioxymethylenebenzyloxy) 
benzamide 
50 
15 n=3 3-cinnam lo benzamide 23 
16 n=2 3- heneth lo benzamide 30 
17 N 3- 4-azidobe lo benzamide 43 
20 (4) NH 3- 4-aminobe lo benzamide 40 
21 (4) COOH 3- 4-carbox ben lo benzamide 0 
23 (4) CH3CO 3-(4-N-acetylamino 
bent lo benzamide 
49 
25 (4) 
COOCH 
3-(4-methylcarboxy 
ben lo benzamide 
insoluble 
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Several of the analogues evaluated were insoluble in the assay medium, so to 
overcome this 3-(carboxybenzyloxy)benzamide 21 was prepared. Whilst 21 was 
more soluble in the physiological buffers the in vitro evaluation was poor. 
Compound 21 possesses an electron withdrawing carboxy group which possibly 
reduces the % inhibition, but may also non-specifically bind to other proteins and 
further lower the degree of PADPRP inhibition. 
Extension of the chain length has been explored, initially by preparing 
phenethylBOB 16 and cinnamylBOB 15. A short extension of chain length was 
tolerated by PADPRP without compromising potency, but this still required further 
exploration. 
5.2 Inhibition of PADPRP by Alkoxybenzamide Analogues 
Table: 5.2. A. PADPRP inhibition by alkoaybenzamide analogues 
0 
NH2 
(CH ,, jn 
H3 
No n compound % inhibition at 10 
26 3 3-but lo benzmide 23 
27 4 3- ent lo benzamide 18 
28 5 3-he lo benzamide 15 
29 6 3-he t lo benzamide 25 
30 7 3-oct lo benzamide insoluble 
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The trend towards a decrease in inhibitory activity was observed as chain length 
increased. This decreasing activity may be due to the insolubility of the analogues, 
because as chain length increased, solubility decreased. The lack of activity may 
also be due to the formation of a hydrophobic tail created by the long chains coiling 
up, thus preventing the drug from binding to or indeed entering the cofactor binding 
region of the enzyme. 
5.3 Inhibition of PADPRP by 2-Substituted Benzoxazole Analogues 
Table: 5.3. A. PADPRP inhibition by 2-Substituted Benzoxazole Analogues 
Rý 
i 
No RI R2 compound % inhibition 
at 10 
39 CONH CH 2-meth lbenzoxazole-4-carboxamide 95 IC 9.8 M 
45 CONH C(CHI)_, 2-tbut lbenzoxazole-4-carboxamide 87 IC 8.4 
43 CONH Ph 2- hen lbenzoxazole-4-carboxamide 82 IC 2.1 M 
53 CONHH PhOCH3 2-(4-methoxyphenyl)benzoxazole-4- Insoluble 
carboxamide 
52 CONH2 PhN02 2-(4-nitrophenyl)benzoxazole-4- Synthesis not 
carboxamide completed 
40 CONHCH3 CH3 2-methylbenzoxazole-4-N- 18 at 100 p. M 
meth lcarboxamide 
38 C02H CH3 2-methylbenzoxazole-4- 0 
carboxylic acid 
51 CO2H PhOCH3 2-(4-methoxyphenyl)benzoxazole 0 
-4-carboxylic acid 
37 H CH 2-methylbenzoxazole 0 
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A series of novel inhibitors were designed where the amide group was restricted 
into the anti conformation by an intramolecular hydrogen bond (Table 5.3. A. ). 
2-Methylbenzoxazole-4-carboxamide 39 was the simplest benzoxazole prepared, 
and the inhibitory activity was promising with an IC50 of 9.8 . tM. Further 
analogues were made, namely, 2-phenylbenzoxazole-4-carboxamide 43 and 2- 
tbutylbenzoxazole-4-carboxamide 45, in order to determine the effects of 
hydrophobicity and steric bulk on potency. Compound 45 exhibited good activity, 
which was comparable with 3-hydroxybenzamide 2, but compound 43 was the most 
active benzoxazole analogue of the series. It is possible that PADPRP possesses a 
hydrophobic pocket with which the 2-substituted moiety associates. Alternatively, 
only the amide moiety binds to the active site, and the higher electron density at the 
carbonyl functionality enhances the binding affinity, thus increasing inhibitory 
activity. 
Further evidence has been obtained for the requirement of an amide group for good 
inhibitory activity. Removal of the amide as for 2-methylbenzoxazole 37, abolished 
inhibitory activity, as did replacing the amide with a carboxylic acid as in 38 and 51. 
A very interesting result was obtained with 2-methylbenzoxazole-4-N- 
methylcarboxamide 40, where one of the amide hydrogens was replaced by a methyl 
group, resulting in a severe loss in inhibitory activity. Because the methyl group is 
present there may be reduced hydrogen bonding in the active site of the enzyme, 
hence loss of activity. 
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5.4 Inhibition of PADPRP by 8-hydroxy-2-[substituted] quinazolin-4[3H]ones 
The most potent PADPRP inhibitors prepared were the product of an interesting 
rearrangement. Although the natural product 2-methylquinazoline-4 [3H] one has 
already been reported as a PADPRP inhibitor, 118 the derivatives 8-hydroxy-2- 
(substituted)quinazolin-4[3hi]ones 69-71 have not. 
Table: 5.4. A Inhibition of PADPRP by 8-hydroxy-2-[substituted] quinazolin-3[3H]ones 
No R1 R2 compound % inhibition 
at 10 M 
69 H CH3 8-hydroxy-2-methylquinazolin- 92 
43 one (ICit) = 0.4 
70 H PhN02 8-hydroxy-2-(4-nitro 92 
phenyl)quinazolin-4 3 one IC = 0.2 
71 CH3 CH3 8-hydroxy-2-methyl-4-N- 5 
meth 1 uinazolin-4-one 
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Compounds 69 and 70 were outstandingly active in vitro with IC50 values of 0.4 
and 0.2 µM respectively. Further experiments were performed to determine the 
effect of a PADPRP inhibitor, specifically 69, on whole cells, and whether by 
inhibiting PADPRP cell death could be attained. 
5.5 Cytotoxicity Testing 
Temozolomide (8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4-(3H)-one), 
is a member of the antitumour imidazotetrazinone series which are currently 
undergoing clinical trials as novel antitumour agents. 119-120 
Figure: 5.5.1. Known monofunctional DNA alkylators 
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R1= H R2 = (CH2)2C1 Mitozolomide 
R1= H R2 = CH3 Temozolomide 
Initially temozolomide is activated in situ by nucleophilic attack at the ring C4 
carbonyl. From this point the action of temozolomide could progress by successive 
SN2 mechanisms (Figure: 5.5.2). Athough there is little evidence for either 
mechanism, the reactive species initially after activation is structurally similar to 5- 
(3,3-dimethyltriazen-1-yl)-imidazole-4-carboxamide (DTIC) which is a precursor of 
a potent alkylating agent. These mechanisms may occur in a laboratory under 
specific chemical conditions, 
however, it is probably a different situation in vivo. 
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Figure: 5.5.2. Possible mechanisms of temozolomide activation 
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Temozolomide is a good DNA monofunctional alkylating agent, whose effects can 
be compromised by DNA repair mechanisms. Inhibition of a repair mechanism, 
such as PADPRP, may result in an increased level of DNA damage and hence 
increased cytotoxicity. 
Clonogenic assays were performed to determine if 8-hydroxy-2-methylquinazolin-4- 
[3H]-one 69 was cytotoxic and, more importantly, whether it potentiated 
cytotoxicity in temozolomide treated cells. The assays determined the effects of 
inhibitor on the ability of cells to grow and divide to form colonies. In the control 
assay, the cells have no inhibitor added, and the numbers of colonies are directly 
proportional to the number of cells plated out. However, in assays which have had 
inhibitors added, and if the inhibitors are cytotoxic, the numbers of colonies will be 
activation 
H ®/ 
NNN-CH3 
DNA 
base 
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considerably reduced. The number of colonies were counted and expressed as a 
percentage of the control. Figure: 5.5.3 shows that increasing concentrations of 
quinazolinone 69 alone are relatively non cytotoxic upto 1 mM, and even at 
concentrations as high as 2 mM the clonogenic potential was only reduced by about 
50 %. It should be noted that the concentrations of quinazolinone 69 used in the 
clonogenic assays are non-cytotoxic (below 0.5 mM), and any potentiation effects 
observed can be directly attributed to the inhibition of PADPRP by quinazolinone 
69. 
Figure: 5.5.3. Cytoxicity of 8-hydroxy-2-methylquinazolin-3[3H]-one 
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Figure: 5.5.4 Synergistic enhancement of temozolomide by 8-hydroxy-2-methylquinazolin- 
4[3H]-one (69) 
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As can be seen from Figure: 5.5.4, treatment of the cells for 16 h with 250 µM 
temozolomide alone caused a 50 % reduction in colonies and to reduce the number 
of colonies to 99 % of the original required 1000 gM temozolomide (-"-). Co- 
incubation of L1210 cells with 250 µM temozolomide and 10 gM 69 caused an 85 
% reduction in colonies (- -). A greater proportion of cell kill was observed at a 
higher concentration of 69 but the same concentration of temozolomide (250 . tM); 
at 50 gM the number of colonies was reduced by 99 %(-"-), and similarly for 100 
pM 69. The effect observed is dose related, and this data can be expressed as dose 
enhancement by examining the concentration of drug required to reduce the number 
of cells to 10 % of original (IC10) for both temozolomide alone, and for the co- 
incubated cells. The IC10 for temozolomide alone is 618 µM, but on co-incubation 
with 10 pM 69 the IC10 was reduced to 367 pM of temozolomide, which is a dose 
enhancement of 1.4; at 50 pM 69 the IC10 was reduced to 125 pM of 
temozolomide which is a 4-fold enhancement and, similarly at 100 µM 69 there was 
a 5-fold enhancement. 
It should be noted that these results are still preliminary and the large error between 
the temozolomide ICI0's can be attributed, in part, to the condition of the cells used 
in the assay. If the cells are not in perfect condition this will be reflected in the 
variability of the results. Further work indicates that the dose enhancement factor 
may be considerably increased. 
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Summary 
Some of the novel PADPRP inhibitors designed and synthesised have proved to be 
extremely active in vitro and show good potentiation of monofunctional alkylating 
agents. O-Alkylation of 3-hydroxybenzamide produces inhibitors that are 
comparable to the parent inhibitor. Of the benzyloxybenzamide analogues, those 
compounds with electron donating substituents enhanced activity slightly, whereas 
electron withdrawing substituents retarded inhibition. Whether there is a tentative 
structure activity relationship is difficult to say, but these results reinforce the idea 
that a good PADPRP inhibitor requires a strong electronegative carbonyl for 
binding to the enzyme active site. 
R 
BOB 
A further method of improving the inhibitory activity against PADPRP was via 
restriction of the amide bond into the anti conformation. This was achieved by the 
formation of a series of benzoxazole-4-carboxamides where the amide was 
conformationally restricted into the required conformation by an intramolecular 
hydrogen bond. This hydrogen bond was confirmed by NMR spectroscopy and X- 
ray crystallography. 
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benzoxazole-4-carboxamide 
The benzoxazole analogues prepared were significantly more active than 3- 
hydroxybenzamide, with 2-phenylbenzoxazole-4-carboxamide being the most 
potent inhibitor having an IC50 of 2.1 p. M. From these results it can be concluded 
that constraining the amide into the anti conformation does increase inhibitory 
activity. 
The necessity of at least one amide proton has been confirmed. In the benzoxazole 
series a substantial loss of activity was observed when the amide was 
monosubstituted, and activity was abolished when the amide or indeed the carbonyl 
are replaced or removed. It may be concluded that substitution of the amide will be 
tolerated so long as the amide conformation remains unaffected. 
A novel series of potent PADPRP inhibitors were prepared as the product of an 
interesting rearrangement. The quinazolin-4[3H]-ones obtained have an amide as 
part of a ring system and are outstandingly active, however, substitution of the 
remaining amide proton caused loss of inhibitory activity. The inhibitors, 
particularly 8-hydroxy-2-methylquinazolin-4[3H]-one have been shown to 
potentiate the effects of temozolomide with a dose enhancement factor of upto 5. 
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8"hydroxy-2-substituted quinazolin-4[3H]-one 
Whilst the in vitro data is still preliminary, these compounds may prove to be a 
useful lead for improved resistance modifing agents in cancer chemotherapy. 
Future Investigations 
The most obvious approach would be to continue the quinazolinone series of 
analogues. The synthetic targets should include preparation of 8-hydroxy-2- 
phenylquinazolin-4[3H]-one and 8-hydroxy-2-(4-methoxyphenyl)quinazolin-4[3H]- 
one. Another valuable analogue would be 8-hydroxy-2-(4-azidophenyl)quinazolin- 
4[3H]-one since it would be predicted that this analogue would have the same order 
of activity as 8-hydroxy-2-methyl)quinazolin-4[31H]-one, providing a useful tool for 
radiolabelling studies 
R=H 
R= OCHS 
R=N3 
Completion of the outstanding analogues should also be considered, the compounds 
2-(4-nitrophenyl)benzoxazole-4-carboxamide and 2-(4-carboxymethylphenyl)- 
be(oxazole-4-carboxamide may shed more light on the mode of binding and 
confirm any putative structure activity relationships. 
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Although the rearrangement of the benzoxazole to the quinazolinone occurred via 
an interesting rearrangement, these conditions do not provide an efficient synthesis 
to these novel potent PADPRP inhibitors. Therefore, alternative routes to this 
compound should be explored. 
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CHAPTER SIX 
Experimental 
7.1 Biological assay 
Hypotonic buffer: 9 mM Hepes; 4.5 mM dextran; 4.5 mM MgC12; 5 mM DTT 
added prior to use, pH adjusted to 7.8. 
Isotonic buffer: 40 mM Hepes; 130 mM KCI; 4% dextran; 2 mM EGTA; 2.3 mM 
MgC12; 225 mM sucrose; 2.5 mM DTT added prior to use, pH adjusted to 7.8. 
NAD cocktail: NAD diluted with water to 600 µM. To this 32P NAD (2-5 µ1/m1) 
was added. 
Exponentially growing L1210 cells (-- 8x 106/ml) were spun down 1,500 rpm for 5 
min. The pellet was resuspended in PBS and respun. The pellet was resuspended 
at 3x 107 cells/ml in cold hypotonic buffer and left on ice for 30 min. 9 Volumes of 
ice cold isotonic buffer were added and the cells checked for number and 
permeabilisation with a haemocytometer and trypan blue as a stain. 
The cells were prewarmed at 26 °C for 7 min. before use and the assay was 
performed at 26 OC in prewarmed tubes. 
To each tube was added: 
Oligonucleotide 5 gM (200 µg/ml); NAD cocktail 50 µl; DMSO + drug 8µl; water 
37 µl. The assay was started by the addition of cell suspension 300 µl. The assay 
tubes were shaken at 26 °C for 5 min. The reaction was stopped by addition of ice 
cold 10 % TCA 10 %, NaPPi solution and the tubes put on ice for 1 h. 
The contents of the tubes were filtered through Whatman GF/C filters (rough side 
up), which were rinsed 6 times with 1% TCA, 1% NaPPi solution. The filters 
were dried, tranferred to vials and the 0 emmision counted. 
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7.2 Synthesis 
All NMR spectra were run on a Bruker Spectrospin AC 200E spectrometer, the 
solvent used was CDC13 unless stated otherwise; J values are given in hertz and S 
values are stated in p. p. m. Mass spectra were obtained on an AE1 MS9 or Kratos 
MS80 in EI mode (unless otherwise stated) or on a Kratos machine using MNBA 
matrix in FAB mode. Infrared spectra were obtained using a Nicolet 205X 
spectrophotometer as KBr discs. Elemental analysis were determined with a Carlo- 
Erba Strumentazione model 1106 elemental analyser. Thin layer chromatography 
was carried out using TLC aluminium sheets pre-coated with Kieselgel 60 F 254, 
0.2 mm and column chromatography was performed using Kieselgel 60. 
All solvents were distilled: Ethanol and methanol were dried using Mg/I2 according 
to 'Vogel', 4th Edn., p 269, and stored over 3A molecular sieves. Diethyl ether and 
tetrahydrofuran were distilled from sodium benzophenone ketyl. Dichloromethane 
was pre-dried over K2CO3 and distilled from CaH2. Acetonitrile was pre-dried 
over K2CO3, distilled from CaH2 and stored over 3A molecular sieves. Pyridine 
was distilled from CaH2 and stored over KOH pellets. Benzene was static dried 
over alumina. The petrol used was in the boiling range 40-60 OC. 
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Experimental For Chapter Two 
3 Acetoigbenzoic acid 4 
3-Hydroxybenzamide (1.0 g, 7.3 mmol) was added to an ice cooled solution of 
sodium hydroxide (0.61 g, 15.25 mmol in 10 ml water). Acetic anhydride (0.81 g, 
9.93 mmol) was added with crushed ice (2 g), and the solution stirred at 0 °C for 1 
h. Acidification with hydrochloric acid (3 ml, 6M) yielded a white precipitate which 
was extracted into dichloromethane (3 x 30 ml). The organics were combined, 
dried, filtered and the solvent removed under reduced pressure to yield a white solid 
which recrystallised from boiling water. (0.75 g, 56%). 
m. p. 122-125°C; v,,, /cm-' 3020,2883,2662,2548,1761,1680,1585,1485, 
1454,1412,1373; ml: 180 (30%, M+), 138 (100%, Mi'-COCH3), 121 (82%, M+- 
000H30H), 110,92,81,65,43 (98%, [COCH3]+); 6g d6-DMSO 2.3 (s, 3H, 
CH3), 7.45 (m, 1H), 7.6 (m, 1H), 7.7 (m, 1H), 7.9 (m, 1H), 13.3 (br. s, 1H, OH); SC 
d6-DMSO 26.09,127.90,131.65,131.87,135.07,137.49,155.72,171.79; Found 
M+ 180.0420 C9H804 requires 180.0422. 
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3-Hydraxybenzamide 2 
Compound 4 (0.5 g, 2.8 mmol) was dissolved in thionyl chloride (1.74 ml, 20 
mmol) and the mixture refluxed for 4 h. The excess thionyl chloride was removed 
via vacuum distillation to yield a yellow oil. The oil was added dropwise to an ice 
cooled solution of ammonia (35 %, 20 ml). The solution was reduced in volume by 
evaporation and the title product 2 allowed to crystallise out of solution. The 
product was collected and recrystallised from water to yield colourless plates (0.14 
g, 37%). 
m. p. 156-158°C; vR, a cm 
1 3402,3244,1653,1614,1597,1506,1450,1402, 
1352; ml: (EI) 137 (96 %, M'), 121 (100 %, M+-NH2), 93 (10 %, M+-CO), 65, 
44; Sg d6-DMSO 7.0 (m, 1H), 7.4 (m, 4H), 9.8 (br. s, 1H); 6C d6-DMSO 114.81, 
118.30,118.41,129.48,136.11,157.15,168.33; Anal. found C 61.48, H 14.97, N 
10.27, C7H7NO2 requires C 61.29, H 15.15, N 10.22 %. 
Preparation of substituted benzyloxybenzamide - General Procedure A. 
Aryl bromide (1 mmol, 1 eq. ) was added to a solution of 3-hydroxybenzamide 
(0.137 g, 1 mmol, 1 eq) and potassium carbonate (0.138 g, 1 mmol) in anhydrous 
acetonitrile (10 ml) and refluxed for 5h. Once the reaction mixture had cooled the 
acetonitrile was removed under reduced pressure and the solids suspended in water 
(20 ml). The organics were extracted into dichloromethane (3 x 30 ml), dried and 
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concentrated under reduced pressure to yield a solid. Recrystallisation from ethyl 
acetate / petrol yielded the product as a solid. 
3-(Benzyloxy)benzamide 5 
The title product was prepared using benzyl bromide (0.137 g, 1.0 mmol) as the 
electrophile in general procedure A. Compound 5 was isolated as a white powder 
(0.253 g, 83 %). 
m. p. 131-132 °C; u,,, cm-1 3317,3119,1635,1610,1595,1419, SH d6-DMSO 
5.25 (s, 2H, OCH2Ph), 7.25 (m, 1H), 7.4 (m, 9H, NH), 8.15 (s, 1H); Sc d6-DMSO 
69.65,113.99,118.12,120.28,128.04,128.22,128.78,129.70,136.05,137.23, 
158.58,167.90; Anal. found C 74.41, H 5.53, N 5.94, required for C14H13NO2 C 
73.98, H 5.77, N 6.17 % 
3-(4-Metl: o. Vbenzylaiy)benZantide 6 
3 
The title product was prepared using 4-methoxybenzyl bromide (0.201 g, 1.0 
mmol) as the electrophile in general procedure A. Compound 6 was isolated as a 
white powder (0.162 g, 63 %). 
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m. p. 156-158 OC; 6H d6-DMSO 3.85 (s, 3H, OCH3), 5.18 (s, 21L OCH2Ph), 7.05 
(d, 2H, J 7.6), 7.25 (m, 9H), 8.05 (s, 1H). SC d6-DMSO 55.53,69.25,112.97, 
117.38,120.0,128.23,129.62,129.25,131.25,136.05,159.46,167.96; Anal. 
found C 70.33, H 5.79, N 5.33, C15H1SNO3 requires C 70.01, H 5.88, N 5.45 %. 
3-(4-Nitrobenzyloxy)benzamide 7 
0 
The title product was prepared using 4-nitrobenzyl bromide (0.184 g, 1.0 mmol) as 
the electrophile in general procedure A. Compound 7 was isolated as a white 
powder (0.156 g, 55 %). 
m. p. 146-149 °C; u, JCnr1 3474,3356,1651,1624,1601,1585,1518,1495,1444, 
1400; m/s 272 (5 %, M+), 137 (100 %, [OHC6H4CONH2]+), 77,51; 5H d6- 
DMSO 5.43 (s, 2H, OCI12Ph), 7.27 (m 1H), 7.53 (m, 4H), 7.83 (d, 2H, J 7.8), 
8.07 (s, 1H), 8.39 (d, 2H, J 8.1); SC d6-DMSO 68.46,114.04,118.15,120.59, 
123.96,128.53,129.79,136.16,145.17,147.34,158.14,167.77; Anal. found C 
61.58, H 4.32, N 9.94, C14H12N204 requires C 61.75, H 4.44, N 10.29 %. 
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3-(4-Fluorobenzyloxy)benzamide 8 
The title product was prepared using 4-fluorobenzyl bromide (0.189 g, 1.0 mmol) 
as the electrophile in general procedure A. Compound 8 was isolated as white 
needles (0.142 g, 58 %). 
m. p. 161-162°C; umJcm-1 3366,3171,1658,1626,1603,1583,1518. m/z 245 (20 
%, M+), 109 (100%, [CH2C6H4F]+), 91,77; 5H d6-DMSO 5.23 (s, 2H, 
OCH2Ph), 7.5 (m, 9H), 8.11 (m, 1H); SC d6-DMSO 68.914,113.951,115.405, 
118.124,120.329,129.329,130.255,133.487,136.056,158.464,164.546, 
167.853; Anal. found C 67.79, H 4.81, N 5.56, C14H12FN02 requires C 67.2, H 
4.8, N5.6%. 
3-(4-Bromoben: yloxy)benzamide 9 
The title product was prepared using 4-bromobenzyl bromide (0.250 g, 1.0 mmol) 
as the electrophile in general procedure A. Compound 9 was isolated as a white 
powder (0.253 g, 83 %). 
m. p. 160-161°C; uma, /cm-' 3323,3146,1670,1622,1601,1581,1489,1462, 
1446; m1z 307 (63%, MH ), 262,212,169, (100%, [BrC6H4CH2]+), 101,90; 6H 
d6-DMSO 5.26 (s, 2H, OCH2Ph), 7.3 (d, 1H, J 6.6), 7.6 (m, 9H); SC d6-DMSO 
107 
68.83,114.03,118.12,120.40,121.25,129.70,130.10,131.69,136.09,136.72, 
158.37,167.84; Anal. found C 54.61, H 3.66, N 4.47, C14H12BrNO2 requires C 
55.26, H 3.29, N 4.47 %. 
3-(4-Trifluoromethylbenzyloxy)benzanside 10 
The title product was prepared using bromotrifluoro-4-xylene (0.239 g, 0.155 ml, 
1.0 mmol) as the electrophile in general procedure A. Compound 10 was isolated 
as a white solid (0.219 g, 74 %). 
m. p. 177-179 OC; m/z 295 (38 %, M+), 159 (100%, [CH2C6H4CF3]+), 135,109, 
91,77; 5H d6-DMSO 5.1 (s, 2H, OCH2Ph), 7.3 (m, 1H), 7.6 (m, 4H), 7.8 (d, 2H, J 
6.8 ), 7.9 (d, 2H, J 6.5), 8.1 (s, 1H); 6C d6-DMSO 68.72,114.01,118.12,120.51, 
125.62,125.69,128.3,129.0,129.77,136.13,142.13,158.29,167.85; Anal. found 
C 61.05, H 3.94, N 5.06, C15H12F3NO2, requires C 61.02, H 4.06, N 4.75 %. 
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3-(4-Cy'anobenzyloxy)benzamide 11 
The title product was prepared using bromo-4-toluonitrile (0.196 g, 1.0 mmol) as 
the electrophile in general procedure A. Compound 11 was isolated as a white 
powder (0.211 g, 84 %). 
m. p. 156-158 °C; u., icm-' 3362,3179,2228,1736,1647,1626,1601,1585, 
1510,1491,1452,1442,1421,1402,1383; m/z 252 (18%, M+), 153,116 (75%, 
[CNC6H4CH2]+), 89,70,61,43 (100%, [O=C=NH]+); SH d6-DMSO 5.3 (s, 2H, 
OCH2Ph), 7.2 (m, 1H), 7.43 (m, 4H), 7.7 (d, 2H, J 6.2), 7.9 (d, 2H, J 6.5), 8.1 (s, 
1H); Anal. found C 71.27, H 4.96, N 10.67, C15H12F3N202 requires C 71.43, H 
4.76, N 11.11 %. 
3-(3-NitrobenZyloxy)ben. -amide 12 
The title product was prepared using 4-bromobenzyl bromide (0.250 g, 1.0 mmol) 
as the electrophile in general procedure A. Compound 9 was isolated as a white 
powder (0.253 g, 83 %). 
m. p. 178-179°C; uJcm-' 3368; 3196,1651,1626,1612,1601,1583,1518,1491, 
1452; mlz 272 (3.8%; M+), 181,136 (100%, M+-CH2C6H4NO2), 89,78; 5H d6- 
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DMSO 5.5 (s, 2H, OCH2Ph), 7.14 (m, 1H), 7.4 (m, 4H), 7.62 (m, 211), 8.0 (br. s, 
1H), 8.02 (m, 1H); 6C d6-DMSO 66.78,113.85,118.17,120.75,125.18,129.49, 
129.54,132.67,134.33,136.13,147.78,158.11,167.77; Anal. found C 61.53, H 
4.11, N 9.98, C14H12N204 requires C 61.75, H 4.44, N 10.29 %. 
3-(2-Nitrobenzyloxy)benzamide 13 
The title product was prepared using 2-nitrobenzyl bromide (0.216 g, 1.0 mmol) as 
the electrophile in general procedure A. Compound 13 was isolated as a yellow 
powder (0.173 g, 64 %). 
m. p. 154-156 OC; umJcm-1 3379,3198,2846,1678,1647,1622,1610,1581, 
1518,1495; m/z 272 (3.8%, M+), 248,217,196,181,136 (100%); 5H d6-DMSO 
5.2 (s, 2H, OCH2Ph), 7.20 (m, 1H), 7.45 (m, 5H), 7.6 (m, 2H), 8.0 (br. s, 1H), 8.1 
(d, 1H, J 7.8); Sc d6-DMSO. 73.78,114.85,119.23,122.75,125.28,129.49, 
129.24,129.54,132.47,134.34,136.24,147.64,158.31,167.77; Anal. found C 
61.49, H 4.42, N 10.11, C14H12N204 requires C 61.75, H 4.44, N 10.29 %. 
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3-(3,4-Methylenedioxyphenylmethyloxy)benzamide 14 
The title product was prepared using (3,4-methylenedioxy)benzyl chloride (0.207 g, 
1.0 mmol) as the electrophile in general procedure A. Compound 14 was 
recrystallised from water and isolated as a white powder (0.265 g, 97 %). 
m. p. 141-142 °C; m/z 271 (6 %; M+), 136 (100%, [OHC6H4CONH2]+), 105,77; S 
H d6-DMSO 5.1 (s, 2H, OCH2Ph), 6.1 (s, 2H, OCH2O), 7.1 (m, 3H) 7.25 (m 1H), 
7.5 (m, 4H), 8.05 (m, 1H); 5c d6-DMSO 69.023,101.36,108.41,108.81,114.01, 
118.19,120.22,121.90,129.61,136.02,147.21,147.64,158.55,167.89; Anal. 
found C 66.18, H 4.47, N 4.94, C15H13N04 requires C 66.42, H 4.78, N 4.94 %. 
3-Cinnamylo. gbenzamide 15 
0 
NH2 
o 
The title product was prepared using (3-chloropropenyl)benzene (0.152 g, 0.138 
ml, 1.0 mmol) as the electrophile in general procedure A. Compound 15 was 
isolated as a white powder (0.114 g, 45 %). 
m. p. 131-133 OC; u., Jcm-1 3381,3196,2914,2864,1630,1612,1597,1579, 
1489,1444,1392,1373,1329; m/z 254 (28%, MH+), 137 (39%, 
[CONH2C6H; OH]+)1117 (100%, [CH2CHCHC6H5]+), 91 (50%), 77; 6H d6- 
DMSO 4.88 (d, 2H, OCH2CHCHPh, J 5.4), 6.65 (dt, 1H, OCH2CHCHPh, J 5.6, 
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16), 6.89 (d, 1H, OCH2CHCHPh, J 16), 7.2 (m, 1H), 7.40 (m, 9H), 8.10 (br. s, 
1H); SC d6-DMSO 73.43,118.86,122.97,125.17,130.04,131.75,133.17,133.96, 
134.66,137.69,141.02,141.39,163.43,172.88; Anal. found C 74.68, H 6.37, N 
5.79, C16H15NO2 requires C 74.65, H 6.27, N 5.81 %. 
3-Phenethylbenxylaxybenzamide 16 
The title product was prepared using (2-bromoethyl)benzene (0.185 g, 0.136 ml, 
1.0 mmol) in general procedure A. Compound 16 was isolated as a white powder 
(0.034 g, 14 %). 
m. p. 132-1341 °C; u, ax/cm-1 3327,3154,2955,2930,2883,1666,1630,1599, 
1583,1491,1450,1402,1387; m/z 241 (9%, M+), 105 (100%, 
[OCH2CH2HC6H4]+), 91 (60%), 91,77; Sg d6-DMSO 3.08 (t, 2H, OCH2CH2Ph, 
J 7.0), 4.1 (t, 2H, OCH2CH2Ph, J 7.0), 6.00 (br. s, 2H), 6.99 (m, 1H), 7.20 (m, 
8H); 6C d6-DMSO 68.35,70.24,113.90,118.09,119.92,123.67,129.22,129.59, 
129.91,135.95,139.00,158.81,167.96; Anal found C 74.68, H 6.37, N 5.79, 
C15H15NO2 requires C 74.65, H 6.27, N 5.81 %. 
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3-(4-Azidobenzyloxy)benzamide 17 
The title product was prepared using 4-azidobenzylbromide 19 (0.2 g, 1.0 mmol) as 
the electrophile in general procedure A. Compound 17 was isolated as a yellow 
solid (0.136 g, 51 %). 
m. p. 167-169 OC; um/cm-1 3341,3155,2121,2094,1664,1631,1610,1583, 
1506,1450; ml: 269 (6%, MH+), 252 (6.1%, M+-NH 2), 233 (M+-CONH2), 167 
(M+-NZ), 137 (38 %, [OHC6H4CONH2]+), 104 (100%, [N3C6H4CH2]+), 93,77; 
6g d6-DMSO 5.27 (s, 2H, OCH2Ph), 7.27 (m, 3H), 7.5 (m, 6H), 8.12 (s, 1H); 
6C d6-DMSO 69.09,114.04,118.16,119.52,120.35,129.73,129.88,134.11, 
136.09,139.33,158.48,167.88; Anal. found C 62.66, H 4.51, N 20.89, 
C14H12N402 requires C 62.14, H 4.30, N 20.7 %. 
4-Azidotoluenel8 79 
H3 
N3 
p-Toluidine (1.0 g, 9.3 mmol, 1 eq. ) was added to a solution of hydrochloric acid at 
0 oC and stirred until dissolved. Sodium nitrite (0.709 g, 10.28 mmol, 1.1 eq. ) in 3 
ml water) was added dropwise over 15 min. and the solution stirred at 0 OC for 30 
min. Sodium azide (2.43 g, 2.43 mmol, 4.0 eq. ) was added slowly over a period of 
30 min [CARE use glass spatula], and the reaction stirred for 1 h. Water was 
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added (100 ml) and sodium hydrogen carbonate was added until the pH = 6. The 
organics were extracted into dichloromethane (3 x 50 ml), combined, dried, filtered 
and the solvent removed under reduced pressure to yield a yellow oil. Flash 
chromatography using petrol as the eluent yielded 18 as an amber oil (0.77 g, 62 
m/z 134 (6%, MH+), 104 (93 %, M+-N2), 90,78 (100% [C6H6]+); 5H 2.5 (s, 3H, 
CH3), 7.02 (d, 2H, J 6.4), 7.9 (d, 2H, J 6.4). 
4-AzidobenUl bromide 19 79 
H2Br 
N3 
N-Bromosuccinimide (0.44 g, 2.48 mmol) and azoisobutyronitrile (0.035 g, 0.214 
mmol) were added to a solution of 18 (0.3 g, 2.2 mmol) in benzene [CARE potent 
carcinogen], and the mixture refluxed for 7 h. The solvent was removed by vacuum 
distillation and the remaining oil dissolved in diethyl ether (50 ml). The ethereal 
phase was washed with water (3 x 20 ml). The organics were dried, filtered and the 
solvent removed under reduced pressure to yield an oil which was purified by 
column chromatography using petrol as the eluent. Compound 19 was isolated as a 
yellow oil (0.27 g, 57 %). 
SH 4.67 (s, 2H, CH2), 7.02 (d, 2H, J 8.3), 7.66 (d, 2H, J 8.2). 
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3-(4-A minobentyloxy)benzamide 20 83 
J 
Triethylamine (0.302 g, 0.415 ml, 2.99 mmol, 4 eq. ) and dithiothreitol (0.460 g, 
2.99 mmol, 4 eq. ) were added to a solution of 3-(4-azidobenzyloxy)benzamide 17 
(0.2 g, 0.746 mmol) in dry methanol (20 ml). The contents were protected from 
light, and the reaction stirred at r. t. for 1 h. The solvents were removed under 
reduced pressure and the remaining solid resuspended in water (20 ml). The 
organics were extacted into dichloromethane (3 x 30 ml), dried, filtered and the 
solvent removed under reduced pressure. Recrystallisation from ethyl acetate and 
petrol yielded 20 as a pale yellow powder (0.099 g, 55 %). 
m. p. 149-151 °C; um, Jcm-' 3385,3177,1643,1597,1577,1522,1493,1448, 
1417,1390,1375; ml: 242 (4%, M+), 225 (9%, M+-NH2), 198 (30%) 137 (95%, 
[OHC6H4CONH2]+), 121 (100%, [OHC6H4CO]+), 106 (88%, [NH2C6H4CH2]+), 
92,77; 6H d6-DMSO 4.99 (s, 2H, NHZ), 5.2 (s, 2H, OCI2Ph), 6.65 (d, 2H, J 6.9 ), 
7.2 (d, 21-L J 7.1 ), 7.45 (m, 5H), 8.05 (s, 1H); SC d6-DMSO 70.24,113.90, 
118.09,119.92,123.67,125.36,129.59,129.91,135.95,149.0,158.81,167.96; 
Anal. found C 68.99, H 5.71, N 11.42, C14H14N202 requires C 69.42, H 5.78, N 
11.57%. 
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3-(4-NAcetyl-4-aminobenzyloxy)benzamide 23 82 
Compound 17 (0.05 g, 0.187 mmol) was dissolved in thiolacetic acid (1.0 ml) and 
stirred for 96 h. On completion the solvent was removed under vacuum distillation 
to yield a yellow solid. The crude material was purified by column chromatography 
using 9: 1 dichloromethane : methanol as the eluent. The sample was triturated 
with water, then recrystallised from ethyl acetate and petrol to yield a yellow 
powder (0.033 g, 64 %). 
m. p. 198-199 °C; m/z 285 (2%; MH+), 148 (92%, [CH2C6H4NH000H3]+), 137 
(10%, [OHC6H4CONH2]+), 121 (20%, [OHC6H4CO]+), 106 (100%, 
[NH2C6H4CH2]+), 92,78; SH d6-DMSO 2.19 (s, 3H, COCH3), 5.2 (s, 2H, 
OCH2Ph), 7.3 (d, 1H), 7.6 (m, 9H), 10.1 (s, 1H, NHCOCH3); SC d6-DMSO 24.33, 
69.50,113.99,118.09,119.19,120.19,128.78,129.66,131.54,136.03,139.36, 
158.59,167.88,168.65; Anal. found C 67.56, H 5.21, N 9.75, C16H16N203 
requires C 67.82, H 5.34, N 9.89 %. 
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3([4-Methyl carboxylJbenzyloxy)benzamide 25 
The title product was prepared using methyl (4-chloromethyl)benzoate (0.184 g, 
1.0 mmol) as the electrophile in general procedure A. Compound 25 was isolated 
as a white powder (0.156 g, 55 %). 
m. p. 162-163 °C; vn, lcm-' 3331,3154,2959,1722,1666,1630,1601,1581, 
1489,1450,1435,1417; m/z 285 (48%; M+), 254 (38%, M+-OCHS), 149 (100%, 
[CH3O00C6H4CH2]+), 121 (75%, [OHC6H4CO]+); 5H d6-DMSO 3.9 (s, 3H, 
CH3), 5.25 (s, 2H, OCH2Ph), 7.25 (d, 1H, J 5.7), 7.4 (m, 5H), 7.6 (d, 2H, J 8.2), 
7.9 (d, 2H, J 8.3); 6c d6-DMSO 52.41,68.94,114.01,118.09,120.45,127.79, 
129.29,129.69,136.09,142.78,158.33,159.25,166.31,167.82; Anal. found C 
67.19, H 5.16, N 4.78, C16H15N04 requires C 67.37, H 5.30, N 4.91 %. 
3-(4-carbozylbenzyloxy)benzan: irle 21 
Sodium hydroxide (0.014 g, 3.5 mmol) in water (5 ml) was added to a solution of 
3([4-methylcarboxyl]benzyloxy)benzamide 25 (0.1 g, 3.5 mmol) in methanol (5 ml). 
The solution was warmed to 40 °C and stirred for 5 h. The solvents were removed 
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under reduced pressure and the remaining solid dissolved in water (15 ml). The 
solution was cooled to about 4 °C and acidified using ice cold hydrochloric acid 
(1.0 K. The organics were extracted into ethyl acetate (3 x 30 ml), dried, filtered 
and the solvent removed under reduced pressure to yield 25 as a white solid (0.073 
g, 77 %). 
m. p. > 230 oC; vmJcm-1 3435,3194,3435-2903,2525,1680,1612,1581,1468; 
m/z 270 (30%; M+-H), 135 (100%, [HOCOC6H4CH2]+), 121 
(75%, [OHC6H4CO]+), 107,90,77; SH d6-DMSO 5.39 (s, 2H, OCH2Ph), 7.25 (d, 
1H, J 5.2), 7.3 (m, 6H), 8.15 (m, 3H), 13.05 (br. s, 1H); Found M+ 271.0836, 
C15H13NO4 requires 271.0845. 
3-(n-Butyloxy)benzamide 26 
ý, cx; 
3-hydroxybenzamide (0.137 g, 1.0 mmol) was dissolved in anhydrous acetonitrile 
(10 ml) and to this was added potassium carbonate (0.138 g, 1.0 mmol) and 1- 
iodobutane (0.184 g, 1.0 mmol) and the mixture refluxed for 20 h. The acetonitrile 
was removed under reduced pressure and the remaining solid dissolved in water (10 
ml). The organics were extracted into dichloromethane (3 x 20 ml), combined, 
dried, filtered and the solvent removed under reduced pressure. The product was 
sublimed to yield 26 as a white solid (0.037 g, 20 %). 
m. p. 114-116°C; vm8, /cm-1 3341,3161,2959,2934,2874,1666,1613,1601, 
1585,1491,1450,1400; nt/z 193 (65 %, M+), 137 (93 %, [OHC6H4CONH2]+), 
121 (100 %, [OHC6H4CO]+), 92,80,65; SH d6-DMSO 0.91 (t, 3H, 
OCHZCH2CH2CH3) J 7.3), 1.48 (m, 2H, OCH2CH2CH2CH3 J 7.3), 1.77 (m, 2H, 
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OCH2CH2CH2CH3, J 7.2,6.4), 3.98 (t, 2H, OCH2CH2CH2CH3, J 6.4), 5.9 (br. d, 
2H, NH2), 7.04 (dt, 1H, J 2.5,1.2), 7.34 (m, 3H); Sc d6-DMSO 13.85,19.25, 
31.27,67.99,113.24,118.78,119.03,129.63,134.73,159.46,169.43; Anal. 
found C 68.53, H 7.98, N 7.26 C11H15NO2 requires C 68.35, H 7.83, N 7.25 %. 
3-(n-Pentyloxy)benzamide 27 
0 CH3 
Potassium carbonate (0.138 g, 1.0 mmol) and 1-iodopentane (0.198 g, 1.0 mmol) 
were added to a solution of 3-hydroxybenzamide (0.137 g, 1.0 mmol) in anhydrous 
acetonitrile (10 ml) and refluxed for 25 h. The acetonitrile was removed under 
reduced pressure and the remaining solid dissolved in water (10 ml). The organics 
were extracted into dichloromethane (3 x 20 ml), combined, dried , 
filtered and the 
solvent removed under reduced pressure. The product was sublimed to yield 27 as 
a white powder (0.077 g, 37 %). 
m. p. 116-118 oC; vm/cm-1 3360,3173,2955,2939,2870,1658,1626,1603, 
1583,1491,1450; m/z (EI) 207 (40 %, M+), 137 (100 %, [OHC6H4CONH2]+) 
121 (85 %, [OHC6H4CO]+), 92,70,65; 6H d6-DMSO 0.91 (t, 3H, 
OCH2CH2CH2CH2CH3, J 7.2), 1.42 (m, 4H, OCH2CH2CH2CH2CH3 J 7.3), 1.78 
(m, 2H, OCH2CH2CH2CH2CH3, J 7.0,6.6), 3.98 (t, 2H, OCH2CH2CH2CHHCH3, J 
6.6), 5.5-6.1 (br. d, 2H), 7.04 (dt, 1H, J 2.5,1.6), 7.33 (m, 3H); 6C d6-DMSO 
14.06,22.48,28.19,28.92,68.27,113.23,118.70,119.04,129.62,134.76,159.44, 
169.50; Anal. found C 69.38, H 8.47, N 6.47 C12H17NO2 requires C 69.54, H 
8.27, N6.76%. 
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General Procedure B: Preparation of alkylmesityl groups. 
Triethylamine ( 9.0 mmol) was added to a solution of alkyl alcohol (6.0 mmol) in 
dichloromethane (10 ml). This was cooled to 0 °C and methanesulfonyl chloride 
(6.0 mmol) was added dropwise over 10 min. The reactants were stirred at 0 °C 
for 2 h. The organic phase was washed sequentially with cold water (10 ml), cold 
hydrochloric acid (10 %, 10 ml), saturated sodium hydrogen carbonate solution (10 
ml) and saturated sodium chloride solution (10 ml). The organics were dried, 
filtered and the solvent removed under reduced pressure. 
Hexan-l-ol 0 n: esylate 
H3C SOSH3 
The product was formed with hexan-l-ol (0.612 g, 0.752 ml) being utilised in 
general procedure B. The title compound was isolated as an oil (0.570g, 40 %). 
Heptan-l-ol 0 mesylate 
H3C 
S%CH3 
The product was formed with heptan-l-ol (0.697 g, 0.849 ml) being utilised in 
general procedure B. The title compound was isolated as a yellow oil (0.450g, 39 
%ý. 
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Octan-l-ol 0-mesylate 
H3 SOZCH3 
The product was formed with octan-l-ol (0.781 g, 0.944 ml) being utilised in 
general procedure B. The title compound was isolated as an oil (0.432 g, 37 %). 
3-(n-hexyloxy)benzamide 28 
Potassium carbonate (0.138 g, 1.0 mmol) and hexan-l-ol O-mesylate (0.26 g, 1.4 
mmol) were added to a solution of 3-hydroxybenzamide (0.137 g, 1.0 mmol) in 
anhydrous acetonitrile (10 ml) and refluxed for 25 h. The acetonitrile was removed 
under reduced pressure and the remaining solid suspended in water (10 nil). The 
organics were extracted into dichloromethane (3 x 20 ml), combined, dried, filtered 
and the solvent removed under reduced pressure. The product was isolated via 
flash chromatography using 19 :1 dichloromethane : methanol as the eluent. The 
product was sublimed to yield 28 a white solid (0.208 g, 94 %). 
m. p. 114-115 °C; vmjcm-1 3364,3173,2955,2939,2870,1657,1626,1603, 
1583,1491,1450,1392; ml: (EI) 221 (63 %, M+), 137 (100 %, 
[OHC6H4CONH2]+) 121 (95 %, [OHC6H4CO]+), 109,92; 5H d6-DMSO 0.81 (t, 
3H; OCHHCH2(CH2)3CH3, J 7.2), 1.41 (m, 6H, OCH2CH2(CH2)3CH3 J 7.3), 1.78 
(m, 2H, OCH2CH2(CH2)3CH3), 4.01 (t, 2H, OCH2CH2(CH2)3CH3, J 6.6), 5.7-6.1 
(bd, 2H), 7.04 (m, 1H), 7.33 (m, 3H); SC d6-DMSO 14.077,22.63,25.72,29.18, 
121 
31.59,68.29,113.24,118.79,119.04,129.63,132.01,159.20,169.39, Anal.. 
found C 70.64, H 8.94, N 6.03 C13H19NO2 requires C 70.56, H 8.65, N 6.33 %. 
3-(n-Heptyloxy)benzamide 29 
Potassium carbonate (0.248 g, 1.79 mmol) and heptan-1-ol O-mesylate (0.339 g, 
1.75 mmol) were added to a solution of 3-hydroxybenzamide (0.239 g, 1.75 mmol) 
in anhydrous acetonitrile (10 ml) and refluxed for 36 h. The acetonitrile was 
removed under reduced pressure and the remaining solid suspended in water (10 
ml). The organics were extracted into dichloromethane (3 x 20 ml), combined, 
dried, filtered and the solvent removed under reduced pressure. The product was 
recrysallised from water and ethanol to yield 29 as a white solid (0.152 g, 3 7%). 
m. p. 110-111°C; Vma, Icm-1 3362,3173,2992,2856,1658,1626,1603,1583, 
1450,1392; m/z (EI) 235 (53 %, M+), 137 (100 %, [OHC6H4CONH2]+) 121 (80 
%, [OHC6H4CO]+), 109,93; 6H d6-DMSO 0.86 (t, 3H, OCHZCH2(CH2)4CH3, J 
7.7), 1.21 (m, 8H, OCH2CH2(CH2)4CH3), 1.76 (m, 2H, OCH2CH2(CH2)4CH3), 
3.97 (t, 2H, OCH2CH2(CH2)4CH3, J 6.5), 5.8-6.2 (br. d, 2H), 7.03 (m, 1H), 7.29 
(m, 3H); Sc d6-DMSO 14.14,22.711,26.05,29.22,29.36,31.86,68.29,113.24, 
118.83,119.04,129.64,134.62,159.47,169.36; Anal. found C 69.15, H 8.86, N 
5.47 C14H21NO2 requires C 71.46, H 8.99, N 5.95 % sample calculated to contain 
0.5 M water. 
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3-(n-Octyloxy)benzamide 30 
/I2 
O CH3 
Potassium carbonate (0.138 g, 1.0 mmol) and octan-1-ol O-mesylate (0.23 g, 1.1 
mmol) were added to a solution of 3-hydroxybenzamide (0.137 g, 1.0 mmol) in 
anhydrous acetonitrile (10 ml), and refluxed for 30 h. The acetonitrile was removed 
under reduced pressure and the remaining solid dissolved in water (10 ml). The 
organics were extracted into dichloromethane (3 x 20 ml), combined, dried , 
filtered 
and the solvent removed under reduced pressure. The product was recrysallised 
from water and ethanol to yield 30 as a white solid (0.182 g, 71%). 
m. p. 109-1100C; vm /cm-' 3366,3173,2955,2937,2922,2856,1932,1658, 
1626,1603,1583,1491,1469,1450; m/z 249 (78 %, M+), 137 (98 %, 
[OHC6H4CONH2]+), 121 (93 %, [OHC6H4CO]+); 6H d6-DMSO 0.86 (t, 3H, 
OCHZCH2(CH2)5CH3, J 6.7), 1.3 (m, IOH, OCH2CH2(CH2)SCH3 ), 1.8 (in, 2H, 
OCH2CH2(CH2)SCH3), 3.97 (t, 2H, OCH2CH2(CH2)SCH3, J 6.6), 5.7-6.2 (bd, 2H), 
7.03 (in, 1H), 7.28 (m, 3H); Sc d6-DMSO 14.14,22.64,26.02,29.07,29.22,31.82, 
68.29,113.23,118.80,119.02,129.63,135.1,159.47,169.35; Anal. found C 
72.04, H 9.55, N 5.43 C15H23NO2 requires C 72.25, H 9.30, N 5.62 %. 
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Experimental for Chapter Three 
Methyl-3-hydroxy-2-nitrobenzoate 33 
3-Hydroxy-2-nitrobenzoic acid (5.0 g, 27.3 mmol) was dissolved in methanol (50 ml). 
Anhydrous hydrogen chloride gas was bubbled through the solution until saturated and 
the mixture refluxed for 16 h. Removal of solvent under reduced pressure yielded a 
beige solid which was dissolved in water (100 ml). Sodium hydrogen carbonate (ca 5 
g) neutralised the solution and the organics were extracted into ethyl acetete (3 x 50 
ml), combined and washed sequentially with saturated brine solution (50 ml), then 
water (20 ml). The organics were dried, filtered and the solvent removed under 
reduced pressure to yield methyl-3-hydroxy-2-nitrobenzoate 33 as a beige solid (4.64 
g, 86 %). 
m. p. 112-114 °C; u, dcm-' 3298,3076,2963,2853,1963,1884,1694,1614,1583, 
1537,1479,1452,1439; m/z 197 (98 %, M+), 165 (100 %, M+-OCHS), 136 (12 %), 
121,107,92; 5H 3.9 (s, 3H, CH3), 7.04 (dd, 1H, J 1.3,6.1), 7.2 (dd, 1H, J 1.1,6.0), 
7.5 (t, 1H, J 6.5); SC 53.46,120.75,121.99,130.63,132.33,135.88,154.88,166.64; 
Found M+ 197.0339 C8H7NO3 requires 197.0324. 
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Methyl-2-amino-3-Hydroxybenzoate 34 96 
Palladium on carbon catalyst (0.5 g) was added to a nitrogen charged flask, this was 
suspended in methanol (150 ml) and methyl 3-hydroxy-2-nitrobenzoate 33 (4.0 g, 20.3 
mmol) was added. The flask was evacuated, then charged with hydrogen. The 
mixture was stirred vigorously for 5 h. 
The flask was again evacuated, then opened to the atmosphere. The mixture was 
filtered through a celite pad to remove the catalyst and the pad washed in portions with 
methanol (4 x 30 ml). The methanol was removed under reduced pressure to yield 34 
as a brown solid (3.34 g, 99 %). 
6H CDC13 3.85 (s, 3H, CH3), 5.57 (br. s, 2H, NH2), 6.48 (t, 1H, J 8), 6.80 (dd, 1H, J 
1.0,6.8), 7.46 (dd, 1H, J 1.1,7.1). 
Etizylacetimidate hydrochloride 36 
NH. HCI 
H CýOCH CH 323 
Anhydrous hydrogen chloride gas was bubbled through a of solution acetonitrile 
(0.263 ml, 5.0 mmol) in dry ethanol (0.69 ml, 15.0 mmol) until saturated and the 
solution stirred for 48 h. The white solid formed 36, was collected and dried. 
m. p. 126-128 °C; umdcm-1 4432,2982,2694,1956,1643,1603,1560,1479,1456; 
m/z 88 (30 %, MH+-HCl), 60 (3 %, MH+-CH2CH3), 42 (100 %, [CH3CN]+), 36,29; 
Sg d6-DMSO 1.38 (t, 3H, J 7.0, CH2CH3), 2.44 (s, 3H, CH3), 4.57 (q, 2H, J 8.0, 
CH2CH3); Found M+-HC187.0707, C4H9NO requires 87.0684. 
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Methyl 2-metl: ylbenzoxazole-4-carboxylate 35 
Ethylacetimidate hydrochloride 36 (0.615 g, 5.0 mmol) was added to a nitrogen 
charged flask containing methyl-2-amino-3-hydroxybenzoate 34 (0.835 g, 5.0 mmol) in 
anhydrous ethanol. The mixture was refluxed for 24 h. The solvent was removed 
under reduced pressure and the remaining solid dissolved in water (20 ml). The 
organics were extracted into ethyl acetate (3 x 15 ml), combined, dried, filtered and the 
solvent removed under reduced pressure. Recrystallisation from ethyl acetate/ petrol 
yielded 35 as a cream solid (0.84 g, 85 %). 
m/z 253 (M+, 100 %), 222 (98 %, M+-OCHS), 195 (97 %, M+-COOCH3), 166,140, 
103,89,77; 6H 4.0 (s, 3H, CH3), 7.35 (t, 1H, J 8.2), 7.45 (m, 3H), 7.75 (dd, 1H, J 
1.0,7.1), 8.0 (dd, 1H, J 1.2,6.9) 8.3 (m, 2H); 5c 13.86,114.97,122.02,124.48, 
126.57,127.12,128.27,128.93,141.72,165.90; Found M+ 191.0579, C10H9NO3 
requires 191.0582. 
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2 Methylbenzoxazole carboxylic acid 38 
Sodium hydroxide (0.052 g, 1.3 mmol) in water (5 ml) was added to a solution of 
methyl 2-methylbenzoxazole-4-carboxylate (0.25 g, 1.3 mmol)) in methanol (5 ml). 
The solution was warmed to 40 OC and stirred for 5 h. The solvents were removed 
under reduced pressure and the remaining solid dissolved in water (15 ml). The 
solution was cooled to about 4 °C and acidified using ice cold hydrochloric acid (0.05 
M) until pH = 4.5. The organics were extracted immediately into ice cold ethyl 
acetate. (3 x 30 ml), dried, filtered and the solvent removed under reduced pressure to 
yield 38 as a yellow solid (0.187 g, 81 %). 
m. p. > 230 T. u., cm-' 2554,1979,1676,1620,1603,1570,1491,1429; m/z 177 
(40 %, M+), 160 (25 %, M+-OH), 133 (100%, M+-COOH), 107,91,77; 6H d6- 
DMSO 2.8 (s, 3H, CH3), 7.5 (m, 1H), 7.97 (m, 2H), 13.0 (br. s, 1H, OH), Sc 14.66, 
114.95,122.80,124.50,126.55,141.01,151.57,165.85,166.52. Found M+ 
177.0426, C9H7N03 requires 177.0425. 
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2-Methylbenzoxazole-4-carboxamirle 39 
Dry thionyl chloride (0.066 g, 0.040 ml, 0.616 mmol)) was added to a solution of 2- 
methylbenzoxazole-4-carboxylic acid (0.1 g, 0.56 mmol) in anhydrous THE with a 
catalytic amount of DMF, and the reaction stirred for 2h under a nitrogen atmosphere. 
Aqueous ammonia (2 ml) was added and the reaction stirred for a further 15 min. The 
solvents were removed under reduced pressure and the product recrysallised from 
isopropanol. The title compound 39 was isolated as a cream solid. (0.83 g, 84 %). 
m. p. 192-193 °C; un, a, t/cm-1 
3375,3200,1965,1878,1674,1626,1595,1574,1431; 
m/z 176 (97 %, M+), 160 (100 %, M{'-NH2), 133 (93 %, M+-CONH2), 106,91,78, 
68; 6g 2.86 (s, 3H, CH3), 5.8 (br. s, 1H, NH), 7.39 (t, 1H, J 8.0), 7.6 (dd, 1H, J 1.1, 
8.0), 8.1 (dd, 1H, J 1.1,8.1), 8.8 (br. s, 1H, NH); Anal. found C 61.2, H 4.41, N 
15.53, C9H9N202 requires C 61.34, H 4.58, N 15.91 %. 
Z-Methylbenzoxazole 4-(N methyl)carboxamide 40 
CH3 
Dry thionyl chloride (0.111 g, 0.068 ml, 0.931 mmol) was added to a solution of 2- 
methylbenzoxazole4-carboxylic acid 38 (0.15 g, 0.846 mmol) in anhydrous THE with 
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a catalytic amount of DMF, and the reaction stirred for 2 h. Aqueous methylamine 
(excess, 2 ml) was added and the reaction stirred for a further 15 min. The solvents 
were removed under reduced pressure and the product 40 recrysallised from 
isopropanol as a white solid (0.117 g, 73 %). 
ucm-1 3344,2932,1658,1601,1570,1481,1425; m/z 190 (71 %, M+), 174 (18 
%), 160 (76 %, M-NHCH3), 133 (100 %, M+-CONHCH3), 116,107 (70 %), 91,74; 
6H 2.65 (s, 31-L CH3), 3.6 (d, 3H, NHCH3), 7.35 (t, 1H, J 8.0), 7.56 (dd, 1H, J 1.1, 
7.1), 8.12 (dd, 1H, J 1.1,6.7), 8.8 (br. s, 1H, NH); Anal. found C 63.46, H 5.50, N 
14.50, C10H10N202 requires C 63.15, H 5.30, N 14.73 %. 
Ethyl benzimidate hydrochloride 41 
NH. HCI 
/I OCHZCH3 
Benzonitrile (10.28 ml, 100.0 mmol) was added to dry ethanol (15 ml, 300 mmol) and 
anhydrous hydrogen chloride gas was bubbled through the solution until saturated. 
The solution was stirred for 48 h ay ambient temperature. The white solid formed 41, 
was collected and dried (9.63 g, 52 %). 
m. p. 126-128 °C; umdcm-1 2856,1915,1631,1601,1585,1541,1506,1454,1441, 
1387,1363,1327,1305; m/z 148 (29 %, M+-HC1), 121 (38 %, M+-CH2CH3), 105 
(100 %, [PhNH]+), 77 (51 %, [Ph]+), 51,42,36; SH d6DMSO 1.56 (t, 3H, J 7.1, 
CH2CH3), 4.77 (q, 2H, J 8.0, CH2CH3), 7.5 (m, 2H), 7.6 (m, 1H), 8.2 (m, 2H); Anal. 
found C 58.13, H 6.43 N 7.36, C9H12NOC1 requires C 58.23, H 6.51, N 7.54 %. 
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Methyl 2-phenylbenzoxazole-4-carboxylate 42 
Ethyl benzimidate hydrochloride 41 (0.222 g, 1.19 mmol) was added to a nitrogen 
charged flask containing methyl 2-amino-3-hydroxybenzoate 34 (0.1 g, 0.59 mmol) in 
anhydrous ethanol (20 ml). The mixture was refluxed for 24 h. The solvent was 
removed under reduced pressure and the remaining solid dissolved in water (20 ml). 
The organics were extracted into ethyl acetate (3 x 15 ml), combined, dried, filtered 
and the solvent removed under reduced pressure. Recrystallisation from ethyl acetate/ 
petrol yielded 42 as a yellow solid (0.127 g, 85 %). 
m. p. 191-193 °C; umjcm-1 2999,2915,1714,1610,1550,1485,1452,1435,1421, 
1356, m/z 253 (M+, 100 %), 222 (98 %, M+-OCHS), 195 (97 %, M+-COOCH), 166, 
140,103,89,77; 6H 4.0 (s, 3H), 7.35 (t, 1H, J 8.2), 7.45 (m, 3H), 7.75 (dd, 1H, J 
1.0,7.1), 8.0 (dd, 1H, J 1.2,6.9) 8.3 (m, 2H); Sc 152.55,114.97,122.02,124.48, 
126.57,127.12,128.27,128.93,132.16,141.72,151.46,165.90,171.34; Found M+ 
253.0716, C15H11NO3 requires 253.0739. 
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2-Phenylbenzoxazole-4-carboxamide 43 
Methyl 2-phenylbenzoxazole-4-carboxylate 42 (0.1 g, 0.56 mmol) was added to a 
solution of methanolic ammonia (2 ml, V/v). This was stirred for 12 h at ambient 
temperature. The solvent was removed under reduced pressure to yield a solid which 
was recrystallised from ethyl acetate / petrol affording 43 as a white solid (0.83 g, 84 
%). 
m. p. 199-201 °C; uma/cnr' 3383,3165,1676,1606,1595,1552,1491,1483,1452, 
1425,1392; m/z 238 (100 %, M+), 222 (68 %, M+-NH2 ), 195 (98 %, M+-CO), 143 
(10 %), 104,91,77,63; 6H 6.01 (br. s, 1H, NH), 7.43 (t, 1H, J 8), 7.57 (m, 3H), 7.74 
(dd, 1H, J 1,7), 8.23 (dd, 1H, J 1.1,7.3), 8.27 (m, 2H), 8.97 (br. s, 1H, NH); Anal. 
found C 70.41, H 4.24 N 11.77, C14HION202 requires C 70.58, H 4.23, N 11.76 %. 
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Methyl-2-tertbutylbenzoxazole-4-carboxylate 44 
0 
tButylcarbonyl chloride (0.865 ml, 7.19 mmol), triethylamine (1.0 ml, 7.19 mmol) and 
pyridinium-4-toluene sulphonate (5 mol %) were added to a solution of 3- 
hydroxyanthranillic ester 34 (1.0 g, 5.99 mmol) in m-xylene (50 ml) and refluxed for 
26 h. The m-xylene was removed under reduced pressure to yield a brown solid which 
was suspended in water. The organics were extracted into ethyl acetate (3 x 30 ml), 
combined, dried, filtered and the solvent removed under reduced pressure to yield a 
yellow solid. The product was isolated by flash column chromatography using 1: 4 
ethyl acetate : petrol as the eluent, and recrysallised from ethyl acetate / petrol to yield 
44 as a yellow solid (0.77 g, 59 %). 
u.. /cm-12970,2874,1927,1867,1811,1709,1618,1597,1562,1487,1464,1431, 
1419,1373,1363; m/z 233 (64 %, M), 218 (50 %, M+-CH3), 202 (43 %, M+-CH3), 
186 (100 %, M+-CH3), 173,160,146 (58 %, M+-OCHS), 117,91; 6H 1.5 (s, 9H, 
C(CH3)3), 3.9 (s, 3H, CH3), 7.2 (t, 1H, J 8), 7.6 (dd, 1H, J 1.0,7.1), 7.9 (dd, 1H, J 
1.1,6.7); Anal. found C 67.10, H 6.76 N 5.94, C13H1SNO3 requires C 66.94, H 6.48, 
N5.94%. 
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2-tertButylbenzoxazole-4-carboxamide 45 
Methyl 2-tbutylbenzoxazole-4-carboxylate 44 (0.2 g, 1.19 mmol) was added to a 
solution of methanolic ammonia (2 ml). This was stirred for 12 h. at ambient 
temperature. The solvent was removed under reduced pressure to yield a solid which 
was recrystallised from ethyl acetate / petrol affording 45 as white plates (0.18g, 69 
%). 
un, /cm-13395.3163,2972,1687,1626,1595,1562,1489,1462,1427,1385,1367, 
1352; m/i 281 (98 %, M+), 186 (96 %, M+-CH3), 175,160,146,133,113,63; 6H 
1.44 (s, 9H, C(CH3)3), 5.9 (br. s, 1H, NH), 7.34 (t, 1H, J 8), 7.59 (dd, 1H, J 1.1,7.0), 
78.06 (dd, 1H, J 1.1,6.7), 8.0 (br. s, 1H, NH); 5c 28.41,34.37,113.90,123.27, 
124.33,125.44,139.37,150.80,166.45,174.47; Anal. found C 66.01, H 6.52, N 
12.52, C12H14N202 requires C 66.02, H 6.47, N 12.84 %. 
General procedure C. "- Acylation of methyl-2-amino-3-Ihydroxybenzoate 34. 
Pyridine (7.19 mmol, 1.2 eq) was added to a nitrogen charged flask containing a 
solution of acid chloride (7.19 mmol, 1.2 eq) dissolved in anhydrous THE (50 ml). 
Methyl-2-amino-3-hydroxybenzoate 34 (1.0 g, 5.99 mmol, 1.0 eq) was added in one 
portion and stirred for 2 h. at r. t. The solvents were removed under reduced pressure 
to yield a solid. Water (50 ml) was added and the organics were extracted into ethyl 
acetate (3 x 30 ml), dried and the solvent removed under reduced pressure. The 
product was recrystallised 
from boiling ethyl acetate / petroleum ether. 
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Methyl 2-(4-nitrobenzoyl)amino-3-hydroxybenzoate 46 
The product was achieved using 4-nitrobenzoyl chloride (1.33 g, 7.19 mmol) in 
general procedure C. The product 46 was isolated as a brown solid (1.47 g, 77 %). 
m. p. 175-176 °C; uma, /cnr' 3443,3113,1697,1649,1604,1552,1527,1493,1468; 
m/z 316 (14 %, M+), 167 (25 %, [NH0006H4NO21+ 104,97,92; 5H 3.91 (s, 3H, 
CH3), 7.25 (m, 2H), 7.6 (dd, 1H, J 1.5,5.9) 8.2 (d, 2H, J 7.9), 8.3 (d, 2H, J 7.9), 
9.12, (s, 1H, NH), 10.10 (br. s, 1H, OH); 6c 53.07,119.57,123.41,124.19,126.42, 
126.70,128.35,129.18,138.41,150.14,157.25,165.23,169.53; Anal. found C 
56.69, H 3.85 N 8.77, C15H12N206 requires C 56.96, H 3.82, N 8.85 %. 
Methyl-2-(4-metltoxybenzoyl)amino-3-hyrlroXybenzoate 47 
3 
The product was prepared using 4-methoxybenzoyl chloride (1.23 g, 7.19 mmol) in 
general procedure C. Compound 47 was isolated as a yellow solid (1.22 g, 67 %). 
m. p. 177-179 °C; umJcm-' 3453,3209,3072,2839,1691,1643,1606,1564,1541, 
1508,1471,1402,1332; m/: 301 (20 %/ M+), 270 (5 %, M{'-OCHS), 135 (100 
%, [NH0006H4OCH3]+), 107,92,77; 6H 3.87 (s, 3H, OCH3), 3.93 (s, 3H, COCH3), 
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6.99 (d, 2H, J 7.1), 7.14 (t, 1H, J 7.9), 7.26 (dd, 1H, J 1.7,6.6), 7.64 (dd, 1H, J 1.6, 
6.1), 8.0 (d, 2H, J8.2), 10.3 (s, 1H, NH), 11.96 (br. s, 1H, OH); Found M+ 301.0956. 
C16Hi5NO5 requires 301.0950. 
Methyl-2-(4-methylcarboxybenzoyl)amino-3-hydroxybenzoate 54 
The product was prepared using 4-methoxybenzoyl chloride (1.23 g, 7.19 mmol) in 
general procedure C. Compound 54 was isolated as a yellow solid (1.22 g, 67 %). 
m. p. 177-179 °C; umaIcm-1 3426 - 2594,1724,1693,1639,1601,1541,1504,1464, 
1435; m/i 329 (85 %, M+), 297 (45 %, M+-COCH3), 163 (100 %, 
[COC6H4COOCH3]+), 135 (78 %, [C6H4000CH3]+), 120 (36 %), 104,76; 5H 3.93 
(s, 6H, 2x COCH3), 7.2 (m, 2H), 7.6 (dd, 1H, J 2.0,7.9), 8.10 (m, 4H), 9.9 (s, 1H, 
NH), 12.10 (br. s, 1H, OH); Found M+ 329.0912. C17H15NO6 requires 329.0899. 
General Procedure D: Cyclisation to form the oxazole moiety 
To a solution of methyl-2-substituted benzoxazole-4-carboxylate (1.0 g, lmol eq) in 
m-xylene (50 ml) was added triethylamine (1.2 eq) and pyridinium-4-toluene 
sulphonate (5 mol %). The mixture was refluxed for 16 h. The m-xylene was removed 
under reduced pressure to yield a brown solid which was suspended in water. The 
organics were extracted into ethyl acetate (3 x 30 ml), combined, dried, filtered and the 
solvent removed under reduced pressure to yield a solid. The product was isolated by 
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flash chromatography using I: 4 ethyl acetate : petrol as eluent and recrysallised from 
ethyl acetate and petrol. 
Methyl-2-(4-nitrophenyl)benzoxazole-4-carboxylate 48 
The product was prepared from 46 (1.0 g, 3.16 mmol) using general procedure D. 
Compound 48 was isolated as a brown solid (0.71 g, 79 %). 
m. p. 213-215 °C; umJcm' 3055,2957,1726,1620,1604,1556,1522,1489,1462, 
1446,1421; m/z 298 (80 %, M+), 160 (43 %, ), 267 ( 100 %, M+-OCHS), 240 (40 %, 
M+-COOCH3), 229,221,163,140 107 (87 %), 88,79,63; 6H 4.05 (s, 3H, CH3), 7.4 
(t, 1H, J8.0), 7.83(dd, 1H, J1.2,7.1), 8.0(dd, 1H, J 1.1,6.7), 8.3 (d, 2H, J 8.1), 8.5 
(d, 2H, J 8.3); Anal. found C 61.17, H 4.53 N 15.50, C15H1ON205 requires C 61.36, H 
4.54, N 15.50 %. 
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Methyl2-(4-methoxyphenyl)benzoxazole-4 carboxylate 49 
The product was prepared from 47 (1.0 g, 3.32 mmol) using general procedure D, and 
the title compound 49 was isolated as a beige solid (0.70 g, 75 %). 
m. p. 103-104 °C; um cm-1 3063,3024,2978,2955,2831,1720,1614,1502,1419, 
1356,1323,1300; m/z 283 (48 %, M+), 252 (38 %, M+-OCHS), 225 (58 %, M+- 
COOCH3), 133,92,77,63 (100 %); ÖH 3.8 (s, 3H, OCH3), 4.03 (s, 3H, COCH3) 
6.9 (dd, 2H, J2.1,4.9), 7.35 (t, 1H, J 8.0), 7.74 (dd, 1H, J 1.1,7.0), 7.99 (dd, 1H, J 
1.1,6.9), 8.28 (dd, 2H, J 2.2,4.7); 6c 52.46,55.48,114.32,114.63,119.05,121.61, 
123.82,126.87,130.11,142.10,151.41,162.81,164.91,165.92; Found M+ 
283.0854. C16H13NO4 requires 283.0845. 
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Methyl2-(4-carboxynzethylphenyl)benzoxazole-4-carboxylate 55 
3 
The product was prepared from 54 (1.0 g, 3.03 mmol) using general procedure D, and 
the title compound 55 was isolated as a yellow solid (0.63 g, 67 %). 
m. p. 105-107 OC; u,,,,, /cm4 2957,1940,1738,1720,1620,1603,1577,1556,1498, 
1437,1423; m/z 311 (83 %, M+), 280 (100 % M+-OCHS), 253 (58 %, M+- 
COOCH3), 220,163,125; 6H 3.8 (s, 3H, OCH3), 4.03 (s, 3H, COCH3), 6.9 (dd, 2H, 
J2.1,4.9), 7.35 (t, 1H, J8.0), 7.74 (dd, IH, J 1.1,7.0), 7.99 (dd, 1H, J 1.1,6.9), 8.28 
(dd, 2H, J2.2,4.7); Found M+ 311.0800. C17H13NO5 requires 311.0793. 
2-(4-Methoxyphenyl)benzoxazole-4-carboxylate 51 
3 
Sodium hydroxide (0.014 g, 0.353 mmol) in water (5 ml) was added to a solution of 
methyl 2-(4-methoxyphenyl)benzoxazole-4-carboxylate 49 (0.1 g, 0.353 mmol) in 
methanol (5 ml). The solution was warmed to 40 0C and stirred for 5 h. The solvents 
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were removed under reduced pressure and the remaining solid dissolved in water (15 
ml). The solution was cooled to about 4 °C and acidified using ice cold hydrochloric 
acid (0.05 M) until pH = 4.5. The organics were extracted immediately into ice cold 
ethyl acetate. (3 x 30 ml), dried, filtered and the solvent removed under reduced 
pressure. The title product 51 was isolated as a white solid (0.071 g 75 %). 
m. p. 187-188 °C; umaýcm-' 3029,1743,1628,1608,1581,1560,1500,1481,1458, 
1433,1423,1398,1356,1329; m/z 269 (91 %, M+), 225 (100 %, M+-CO2 ), 182 (18 
%), 182,154,135,113,92; 6H d6DMSO 3.98 (s, 3H, CH3), 7.28 (d, 2H, J 8.9), 7.57 
(t, 1H, J 8.0), 7.98 (dd, 1H, J 1.0,7.2), 8.12 (dd, 1H, J 1.1,7.1) 8.10 (d, 2H, J 8.9), 
13.2 (br. s, 1H, OH); Anal. found C 66.50, H 4.08 N 5.08, C15H11N04 requires C 
66.90, H 4.12, N 5.20 %. 
2-(4-Methoxyphenyl)benzoxazole-4-carboxamide 53 
Dry thionyl chloride (1.1 eq) was added to a solution of 2-methylbenzoxazole-4- 
carboxylic acid 51 (0.1 g, 0.371 mmol) in anhydrous THE and the reaction stirred for 2 
h. Aqueous ammonia (excess) was added and the reaction stirred for a further 15 min. 
The solvents were removed under reduced pressure and the product recrysallised from 
isopropanol, yielding 53 as a yellow solid (0.077 g 78 %). 
m . p. 
221-223 °C; um/cm4 3370,3298,3169,2924,2845,1680,1610,1599,1562, 
1502,1462,1441,1377,1354,1356; m/z 268 (93 %, M+), 252 (52 %, M+-NH2 ), 
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237 (5 %, M+-OCHS), 225 (100 %, M+-CO), 209,182,135,126 (20 %), 119,97,91; 
8H 3.89 (s, 3H, CH3), 6.03 (br. s, 1H, NH), 7.01 (d, 2H, J 4.9), 7.41 (t, 1H, J 7.8), 
7.71 (dd, 1H, J 1.0,7.1), 8.16 (dd, 1H, J 1.1,6.8) 8.21 (d, 2H, J 4.9), 9.02 (br. s, 1H, 
NH); Anal. found C 66.08, H 4.38, N 10.05, C15H12N203 requires C 67.14, H 4.51, N 
10.45 %. 
3 Acetoxy-2-nitrobenzoic acid 57 
3-hydroxy-2-nitrobenzoic acid (0.1 g, 0.546 mmol) was added to a cooled solution of 
sodium hydroxide (0.2 M, 3 ml). Upon dissolution, acetic anhydride (0.114 ml) was 
added with crushed ice (1.0 g), this was left to warm to ambient temperature then 
stirred for 16 h. The solution was neutralised with hydrochloric acid (6 M, 5 ml) and 
the organics extracted into ethyl acetate (3 x 20 ml). The organics were dried, filtered 
and the solvent removed under reduced pressure to yield a yellow solid 57 (0.112 g, 91 
%). 
v/cm-1 3300,3092,2897,2683,1977,1776,1705,1614,1583,1543,1527,1469, 
1454,1419,1352; m/: 183 (63 %, M+-COCH3), 165 (42 %, -H20), 121 (55 %, M+- 
C02), 107,91,81,63,52,43 (100 %, [HCOCH3]+); SH d6-DMSO 2.1 (s, 3H, CH3), 
7.5 (m, 3H), 11.35 (br. s, 1H OH); Found M+-000H3 183.0160. C7HSNO5 requires 
183.0168. 
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3-Hydroxy-2-nitrobenzamide 58 
Triethylamine (0.6 ml, 4.31 mmol) was added to a solution of 3-acetoxy-2- 
nitrobenzoic acid 57 (1.0 g, 3.92 mmol) in anhydrous THE (150 ml) at 0 OC under a 
nitrogen atmosphere. Isobutyl chloroformate (0.61 ml, 4.70 mmol) was added 
dropwise to the solution. This was stirred for 1h at 0 °C. On addition of excess 
aqueous ammonia (3.0 ml) the solution turned dark yellow, and the reaction stirred for 
a further 4 h. The solvent was removed under reduced pressure and the remaining 
solid dissolved in water (100 ml). The organics were extracted into ethyl acetate (3. x 
50 ml), dried, filtered and the solvent removed under reduced pressure to yield a 
yellow solid. The title compound was isolated via flash chromatography using 1: 9 
methanol : dichloromethane as the eluent. The title compound 58 was isolated as a 
cream solid (0.41 g, 58 %). 
m. p. 123-126 °C; Uma, /cm-1 3366,3182,1658,1622,1604,1583,1541,1469,1454, 
1394,1338; m/: 182 (M+, 57 %), 165 (100 %, M+-NH2), 121 (56 %), 92,63; 61, d6- 
DMSO 7.25 (dt, 2H, J 1.1,6.6), 7.5 (t, 1H, J 8.7), 7.73 (br. s, 1H), 8.2 (br. s, 1H), 11.2 
(br. s, 1H); Found M+ 182.0332. CANZO4 requires 182.0327. 
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2-Amino-3-hydroxybenzamide 59 
To a flask charged with nitrogen was added a palladium on carbon catalyst (0.2 g), this 
was then suspended in methanol (100 ml) and 3-hydroxy-2-nitrobenzamide 58 (1.0 g, 
5.49 mmol) was added in one portion. The flask was evacuated, then charged with 
hydrogen and the mixture stirred vigorously for 5 h. 
The flask was again evacuated, then opened to the atmosphere. The mixture was 
filtered through a celite pad which was washed in portions with methanol (4 x 30 ml). 
The methanol was removed under reduced pressure to yield 59 as a red solid (0.79 g, 
94%). 
m. p. 193-195 °C; m/z 152 (48 %, M+), 135 (57 %, M+-OH), 105 (55 %), 87,74,62, 
44 (100 %, [CONH2]+); SH d6-DMSO 6.16 (br. s, 2H, NH2), 6.45 (t, 1H, J 7.8), 6.86 
(dd, 1H, J 1.2,6.4), 7.18 (dd, 2H, J 1.2,6.9), 7.7 (br. s, 1H, NH), 9.6 (br. s, 1H, NH); 
5c d6-DMSO 114.447,116.026,119.704,139.948,145.168,171.936; Anal. found M+ 
152.0583. C7H8N202 requires 152.0585. 
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2-([4-methylcarboxybenzoylJamino)-3-Itydroxybenzan: ide 60 
Mono methylterephthalic acid (1.0 g, 5.46 mmol) was dissolved in excess thionyl 
chloride (10 ml) and stirred for 2h at r. t. Any remaining thionyl chloride was removed 
by vacuum distillation to yield a white solid (0.931 g, 86 %), which was used 
immediately. To a flask charged with nitrogen containing anhydrous THE (50 ml) was 
added the freshly prepared acid chloride (0.718 g, 3.62 mmol, 1.1 eq) and pyridine 
(3.62 mmol), this was stirred for 15 min. 3-Hydroxyanthranilic amide 59 (0.5 g, 3.29 
mmol) was added in one portion, and the reaction stirred for a further 2 h. The solvent 
was removed under reduced pressure and the remaining solid dissolved in water (100 
ml). The organics were extracted into ethyl acetate (3 x 50 ml), dried, filtered and the 
solvent removed under reduced pressure to yield a brown solid. The title compound 
60 was purified via flash chromatography using 1: 9 methanol : dichloromethane as 
the eluent, which yielded 60 as a brown solid (0.63 g, 61 %). 
umdcm-' 3397,3339,3248,1946,1726,1711,1657,1641,1616,1581; m/z 314 (6 
%, M+), 163 (98 %, [HONH2C6H3CONH2]+), 155 (100 %, [NH0006H4OCH3]+), 
149,35,105,91,77; 6H 4.02 (s, 3H, COOCH3), 7.22 (m, 3H), 7.6 (br. s, 1H, NH), 
7.86 (br. s, 1H, NH), 8.0 (d, 4H, J 7.9), 10.3 (s, 1H, NH), 11.96 (br. s, 1H, OH); 
Found M+ 314.0906. C16H14N205 requires 314.0902. 
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2,3-methylenedioxybenzoic acid 62 
2,3-Dihydroxybenzoic acid (0.5 g, 3.25 mmol) was suspended in water (10 ml), and 
potassium hydroxide was added (0.542 g, 10.4 mmol), followed by diiodomethane 
(0.968 ml, ) in methanol (1.43 ml). The mixture was refluxed with vigorous stirring 
for 16 h. On cooling the mixture was acidifed with concentrated hydrochloric acid 
until pH = 2, extracted into ethyl acetate, dried, filtered and the solvent removed under 
vacuum to yield a brown powder (0.338 g, 63 %). 
m. p. 224-226 OC (lit m. p. 227 0C); uma, /cm-1 3424-3061,1954,1871,1678,1633, 
1597,1502,1479,1454; m/z 166 (48 %, M+), 138 (31 %, M+-CO), 121 (35 %, M-- 
H20), 109,74,65 (100 %); SH d6-DMSO 6.2 (s, 2H, CH2), 6.9 (t, 1H, J 8.0), 7.2 
(dd, 1H, J 1.3,6.4), 7.3 (dd, 1H, J 1.3,6.8); Sc d6-DMSO 57.184,116.226,119.997, 
129.848,131.787,150.799,165.795. 
2,3-Metl: ylenedioxybenzami(le 63 
2,3-Methylenedioxybenzoic acid (0.2 g, 1.20 mmol) was dissolved in anhydrous THE 
(10 ml) and thionyl chloride ( 0.156 g, 0.096 ml, 1.33 mmol) was added. This was 
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stirred for 2 h, then excess concentrated ammonia (2 ml) was added and the reaction 
stirred for a father 15 min. The solvents were removed under reduced pressure, and 
the product sublimed to yield a white powder ( 0.184 g, 93 %) 
m. p. 176-177 °C (lit m. p. 176 oC); umJcm-1 3474,3240,3186,2918,2851,1675, 
1657,1614,1591,1500,1477; m/z 165 (100 %, M+), 149 (31 %, W-NH2), 136 (41 
%, M+-CO), 65; SH d6-DMSO 6.2 (s, 2H, CH2), 7.02 (t, 1H, J 8.0), 7.2 (dd, 1H, J 
1.2,6.4), 7.28 (br. s, IH, NH), 7.38 (dd, 1H, J 1.3,6.6), 7.78 (br. s, 1H, NH); Sc d6- 
DMSO 101.89,111.51,116.69,121.73,121.79,145.84,147.99,164.76; Anal. found 
C 58.03, H 4.41, N 8.32, C8H7NO3 requires C 58.17, H 4.27, N 8.48 %. 
3-Methoxy-2-nitrobenzamide 64 
Thionyl chloride (5 ml) was added to a dry, nitrogen purged flask containing 3- 
methoxy-2-nitrobenzoic acid (1.0 g, 5.07 mmol). The mixture was refluxed for 4 h. 
Excess thionyl chloride was removed by vacuum distillation to yield a yellow solid. 
The solid was dissolved in anhydrous THE (30 ml), and aqueous ammonia was added 
dropwise forming a white solid. After stirring for 30 min. the solvents were removed 
under reduced pressure to yield a white solid which was recrystallised from hot ethyl 
acetate and petrol to afford 64 as a white solid (0.878 g, 88 %). 
m. p. 209-210 °C; umJcm-l 3348,3179,2984,2951,1672,1626,1610,1579,1537, 
1468,1437,1394,1305; m/: 196 (100 %, M+), 180 (64 %, M+-NH2), 149 (35 %), 
106 (35 %), 92,76 (70 %); SH d6-DMSO 3.9 (s, 3H, CH3), 7.45 (dd, IH, J 1.1,6.5), 
7.5 (dd, 1H, J 1.1,7.5), 7.7 (t, 1H, J 6.8), 7.83 (br. s, 1H, NH), 8.3 (br. s, 1H, NH); Sc 
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d6-DMSO 57.18,116.22,119.99,129.84,131.78,150.79,165.79; Found M+ 
196.0495. C8H8N204 requires 196.0484. 
2-Amino-3-niethoxybenzamide 65 
To a flask charged with nitrogen was added palladium on carbon catalyst (0.20 g), this 
was suspended in methanol (30 ml) and 3-methoxy-2-nitrobenzamide (0.5 g, 2.55 
mmol) was added. The flask was evacuated, then charged with hydrogen. The 
mixture was left to stir vigorously for 5 h. The flask was evacuated, then opened to 
the atmosphere. The mixture was filtered through a celite pad and the pad washed 
with methanol (4 x 10 ml). The solvent was removed under reduced pressure to yield 
a white solid 65 (0.426 g, 99 %). 
m. p. 146-147 OC; m/z 196 (100 %, M+, 180 (64 %, M+-NH2), 149 (35 %), 106 (35 
%), 92,76 (70 %); 6H d6-DMSO 3.9 (s, 3H, OCH3), 6.3 (br. s, 2H, NH2), 6.57 (t, IH, 
J8.0), 6.98 (dd, 1H, J 1.1,6.9), 7.19 (br. s, 1H, NH), 7.27 (dd, 1H, J 1.1,7.0), 7.83 
(br. s, 1H, NH); Sc d6-DMSO 57.18,116.22,119.99,129.84,131.78,150.79,165.79; 
Found M+ 166.0748, C8H10N202 requires 166.0742. 
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3-Methoxy-2-diazonium tetrafluoroborate benzamide 66 
0 
NH2 
NZ+BFý 
CH3 
Fluoroboric acid (1 ml) [CARE] was added to a solution of 2-amino-3- 
methoxybenzamide 65 (0.2 g, 1.02 mmol) in water (1 ml). Sodium nitrite (0.07 g, 1.02 
mmol in 0.2 ml water) was added dropwise and the solution stirred for 1 h. The 
precipitate formed 66 was collected and dried (0.159g, 62 %). 
m. p. 177-178 oC; u cnr1 3474,3366,3335,3154,3154,2957,1668,1618,1593, 
1549,1469,1437,1414; m/s (FAR) 178 (100 %, M+); 6H d6-DMSO 4.39 (s, 3H, 
OCH3), 8.05 (dd, 2H), 8.4 (t, 1H, J8.6) 8.62 (br. s, 1H, NH), 8.97 (br. s, 1H, NH). 
Experimental for Chapter Four 
8-Hydroxy-2-methylquinazolin-4[3HJ-one 69 
Methyl-2-methylbenzoxazole-4-carboxylate 35 (0.1 g, 0.523 mmol) was placed in an 
autoclave, to this was added excess liquid ammonia (30 ml). The autoclave was sealed 
and set to 550C, 20 bar pressure and left for 20 h. Once the autoclave had cooled, the 
material was removed and the excess ammonia evaporated. The product was 
recrystallised from propan-2-ol to yield 69 a cream solid (0.058 g, 63 %). 
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Uma/Cm-1 3177,3036,2999,2882,2808,1670,1626,1577,1512,1473; m/z 176 
(100%, M+), 160 (43 %), 148 (25 %), 134,107 (87 %), 88,79,63; SH d6-DMSO 
2.47 (s, 3H, CH3), 7.25 (dd, IH, J 1.5 6.2), 7.35 (t, 1H, J 7.7), 7.6 (dd, 1H, J 1.5, 
6.2); Sc d6-DMSO 21.75,115.72,118.45,121.76,126.54,138.28,152.59,152.87, 
162.07; Anal: found C 61.17, H 4.53 N 15.50, required for C9H8N202 C 61.36, H 
4.54, N 15.50 %. 
8-Hydroxy-2-(4-nitrophenyl)quinazolin-4[3H]-one 70 
Methyl-2-(4-nitrophenyl)benzoxazole-4-carboxylate 48 (0.20 g, 0.671 mmol) was 
placed in an autoclave, to this was added excess liquid ammonia (50 ml). The 
autoclave was sealed and set to 55°C, 20 bar pressure. This was left for 20hr. Once 
the autoclave had cooled, the material was removed and the excess ammonia 
evaporated. The product was recrystallised from propan-2-ol to yield 70 a yellow 
solid (0.098 g, 52 %). 
vcm-1 3410,1686,1522,1471,1385,1352. m/z 283 (35%, M+), 267 (70%, M+- 
NH2), 253 (20%), 240, (30%, M+-CO) 221,97,85,69,57 (100%); 5H d6-DMSO 
7.38 (dd, 1H, J 1.5,6.2), 7.51 (t, 1H, J 7.7), 7.7 (dd, 1H, J 1.5,6.2) 9.95 (br. s, 1H, 
NH), 12.85 (brs, IH, OH); Sc d6-DMSO 116.03,119.08,122.35,123.77,128.35, 
129.70,137.53,138.70,148.80,149.21,153.72,162.41; Anal. found C 58.22, H 2.97 
N 14.27, required for C14H9N304 C 59.37, H 3.202, N 14.835 % (calculated to 
contain 0.3 M water). 
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8-Hydroxy-2-methyl N methylquinazolin-4-one 71 
To a solution of methyl-2-methyl benzoxazole carboxylate 35 (0.05 g, 0.262 mmol) in 
ethanol (5 ml) was added methylamine (33% in ethanol, 0.2 ml). This was stirred at rt 
for 24h. The solvents were removed under reduced pressure and the solid sublimed to 
yield the title product 71 as a white powder (0.042 g, 85 %). 
u/cm-1 3387,1687,1657,1599,1583; m/z 190 (87%, M+), 148 (15%, ), 133 (18 
%), 111,85,69,56 (100%); 5H d6-DMSO 2.58 (s, 3H, NCH3), 3.58 (s, 3H, CH3), 7.2 
(dd, 1H, J 1.4,6.8), 7.29 (t, 1H, J 7.8), 7.68 (dd, 1H, J 1.3,6.4); Sc d6-DMSO 23.56, 
31.17,116.50,117.05,120.11,127.16,135.76,150.92,153.73,161.56. Anal. found 
C 62.13, H 5.15 N 14.40, required for C1OH10N202 C 63.15, H 5.29, N 14.73 %. 
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Appendix 1: Crystallographic data for 2-methylbenzoxazole-4-carboxamide 
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Table 1. Crystal data, structure solution and refinement for rjg2. 
Identification code rjg2 
Chemical formula C9H8N202 
Formula weight 176.17 
Temperature 160(2) K 
Radiation and wavelength MoKa, 0.71073 A 
Crystal system, space group orthorhombic, Pna21 
Unit cell dimensions a-7.3482(10) Aa- 900 
b- 15.712(2) Aß- 90 0 
c-6.9114(8) A ry - 90° 
Volume 797.9(2) A3 
Z 4 
Density (calculated) 1.467 g/cm3 
Absorption coefficient p 0.107 mm -1 
F(000) 368 
Reflections for cell refinement 35 (9 range 11.46 to 12.45°) 
Crystal colour colourless 
Crystal size 0.39 x 0.34 x 0.29 mm 
Data collection method Stoe-Siemens diffractometer, 
w/8 scans with on-line profile fitting 
8 range for data collection 2.59 to 24.97° 
Index ranges -8 <h<8, -18 <kS 18, -8 5Q58 
Standard reflections 5 every 60 minutes 
Intensity decay of standards 0% 
Reflections collected 2648 
Independent reflections 1399 (R - 0.0103) ini 
Reflections with I>2a(I) 1380 
Absorption correction none 
Structure solution direct methods 
Refinement method full-matrix least-squares on F2 
Weighting parameters a, b 0.0353,0.1069 
Data / restraints / parameters 1399 /1/ 126 
Goodness-of-fit on F2 1.089 
Final R indices (I>2o(I)] R1 - 0.0222, wR2 - 0.0586 
R indices (all data) R1 - 0.0228, wR2 - 0.0596 
Absolute structure parameter 0.1(9) 
Extinction coefficient 0.042(3) 
Largest and mean shift/esd -0.001 and 0.000 
Largest diff. peak and hole . 157 and -. 119 eA-3 
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Table 2. Atomic coordinates (x 104) and equivalent isotropic displacement 
parameters (A2 x 103) for rjg2. U(eq) is defined as one third of the trace of 
the orthogonalized Uij tensor. 
Xyz U(eq) 
C(1) 1624(2) 6795.2(8) 10074(2) 24.0(3) 
0(1) 1289.4(11) 6049.7(5) 9085.1(14) 26.2(2) 
C(2) 2312(2) 6888.4(9) 11918(2) 28.4(3) 
C(3) 2485(2) 7725.0(9) 12550(2) 30.4(3) 
C(4) 2005(2) 8413.1(8) 11375(2) 27.2(3) 
C(5) 1338(2) 8307.4(8) 9505(2) 22.2(3) 
C(6) 1143.6(14) 7464.3(7) 8864(2) 20.9(3) 
N(1) 498.6(13) 7125.8(6) 7112(2) 22.2(2) 
C(7) 610(2) 6310.7(7) 7335(2) 23.6(3) 
C(9) 94(2) 5628.5(8) 5974(2) 30.3(3) 
N(2) 215(2) 8915.8(7) 6522(2) 28.9(3) 
C(8) 867(2) 9066.9(7) 8297(2) 23.5(3) 
0(2) 1101.5(12) 9797.4(5) 8915(2) 31.8(2) 
152 
Table 3. Bond lengths (A) and angles (o) for rjg2. 
C(1)-0(1) 1.378(2) C(1)-C(2) 1.379(2) 
C(1)-C(6) 1.389(2) 0(1)-C(7) 1.371(2) 
C(2)-C(3) 1.391(2) C(3)-C(4) 1.398(2) 
C(4)-C(5) 1.392(2) C(5)-C(6) 1.404(2) 
C(5)-C(8) 1.497(2) C(6)-N(1) 1.405(2) 
N(1)-C(7) 1.292(2) C(7)-C(9) 1.476(2) 
N(2)-C(8) 1.338(2) C(8)-0(2) 1.237(2) 
0(1)-C(1)-C(2) 127.86(11) 0(1)-C(1)-C(6) 107.44(11) 
C(2)-C(1)-C(6) 124.69(12) C(7)-0(1)-C(1) 104.35(9) 
C(1)-C(2)-C(3) 115.11(12) C(2)-C(3)-C(4) 121.68(12) 
C(5)-C(4)-C(3) 122.43(12) C(4)-C(5)-C(6) 116.20(12) 
C(4)-C(5)-C(8) 120.29(11) C(6)-C(5)-C(8) 123.51(11) 
C(1)-C(6)-C(5) 119.88(13) C(1)-C(6)-N(1) 108.54(10) 
C(5)-C(6)-N(1) 131.58(11) C(7)-N(1)-C(6) 104.53(10) 
N(1)-C(7)-0(1) 115.13(11) N(1)-C(7)-C(9) 128.85(13) 
0(1)-C(7)-C(9) 116.01(11) 0(2)-C(8)-N(2) 122.09(12) 
0(2)-C(8)-C(5) 120.96(11) N(2)-C(8)-C(5) 116.93(11) 
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Appendix 2: Crystallographic data for 8-hydroxy-2-methylquinazolin-4[3H]-one 
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Table 1. Crystal data, structure solution and refinement for rjgl. 
Identification code rjgl 
Chemical formula C9H8N202 
Formula weight 176.17 
Temperature 297(2) K 
Radiation and wavelength MoKa, 0.71073 A 
Crystal system, space group monoclinic, C2/c 
Unit cell dimensions a- 24.568(10) Aa- 900 
b-4.856(2) Aß- 131.00(2)° 
c- 18.149(8) A -y - 90 
0 
Volume 1634.0(12) A3 
Z 8 
Density (calculated) 1.432 g/cm3 
Absorption coefficient p 0.104 mm -1 
F(000) 736 
Reflections for cell refinement 36 (B range 11.03 to 12.42°) 
Crystal colour colourless 
Crystal size 0.48 x 0.26 x 0.05 mm 
Data collection method Stoe-Siemens diffractometer, 
w/8 scans with on-line profile fitting 
B range for data collection 2.97 to 22.52° 
Index ranges -22 <h5 26, -5 <k55, -19 SPS 19 
Standard reflections 5 every 60 minutes 
Intensity decay of standards 1% 
Reflections collected 1450 
Independent reflections 1068 (R - 0.0141) ini 
Reflections with I>2a(I) 769 
Absorption correction none 
Structure solution direct methods 
Refinement method full-matrix least-squares on F2 
Weighting parameters a, b 0.0524,1.2790 
Data / restraints / parameters 1064 /0/ 121 
Goodness-of-fit on F2 1.087 
Final R indices (I>2o(I)] R1 - 0.0357, wR2 - 0.0939 
R indices (all data) Rl - 0.0584, wR2 - 0.1189 
Extinction coefficient 0.0044(11) 
Largest and mean shift/esd 0.001 and 0.000 
Largest diff. peak and hole . 199 and -. 144 eA73 
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Table 2. Atomic coordinates (x 104) and equivalent isotropic displacement 
parameters (A2 x 103) for rjgl. U(eq) is defined as one third of the trace of 
the orthogonalized Ui3 tensor. 
xyz U(eq) 
C(1) 6176.5(13) 2773(5) 8032(2) 48.2(7) 
0(1) 5862.6(11) 4391(4) 8279(2) 63.7(6) 
C(2) 6907.8(14) 2914(6) 8582(2) 56.1(7) 
C(3) 7253.8(14) 1280(6) 8369(2) 59.4(8) 
C(4) 6862.6(13) -507(6) 7593(2) 53.2(7) 
C(5) 6113.9(12) -639(5) 7011(2) 42.2(6) 
C(6) 5760.2(12) 1023(5) 7218(2) 41.7(6) 
N(1) 5010.1(10) 1026(4) 6635.8(14) 44.1(6) 
C(7) 4642.2(13) -673(5) 5903(2) 41.9(6) 
C(9) 3840.4(13) -819(6) 5238(2) 54.1(7) 
N(2) 4958.6(10) -2399(4) 5688.1(13) 45.2(6) 
C(8) 5684.5(12) -2483(5) 6187(2) 44.4(6) 
0(2) 5925.4(9) -4046(4) 5918.1(12) 57.2(6) 
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Table 3. Bond lengths (A) and angles (o) for rjgl. 
C(1)-0(1) 1.367(3) C(1)-C(2) 1.370(4) 
C(1)-C(6) 1.403(3) C(2)-C(3) 1.390(4) 
C(3)-C(4) 1.372(4) C(4)-C(5) 1.398(3) 
C(5)-C(6) 1.405(3) C(5)-C(8) 1.443(3) 
C(6)-N(1) 1.399(3) N(1)-C(7) 1.300(3) 
C(7)-N(2) 1.362(3) C(7)-C(9) 1.491(3) 
N(2)-C(8) 1.372(3) C(8)-0(2) 1.243(3) 
0(1)-C(1)-C(2) 119.0(2) 0(1)-C(1)-C(6) 121.0(2) 
C(2)-C(1)-C(6) 119.9(2) C(1)-C(2)-C(3) 121.2(2) 
C(4)-C(3)-C(2) 120.1(2) C(3)-C(4)-C(5) 119.5(3) 
C(4)-C(5)-C(6) 120.6(2) C(4)-C(5)-C(8) 121.1(2) 
C(6)-C(5)-C(8) 118.3(2) N(1)-C(6)-C(1) 118.9(2) 
N(1)-C(6)-C(5) 122.5(2) C(1)-C(6)-C(5) 118.5(2) 
C(7)-N(1)-C(6) 117.3(2) N(1)-C(7)-N(2) 122.6(2) 
N(1)-C(7)-C(9) 121.4(2) N(2)-C(7)-C(9) 116.0(2) 
C(7)-N(2)-C(8) 124.6(2) 0(2)-C(8)-N(2) 120.4(2) 
0(2)-C(8)-C(5) 125.0(2) N(2)-C(8)-C(5) 114.6(2) 
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